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Abstract 
 
 
Statement of the problem: Survival rates of low-grade gliomas (diagnosed and treated during 
childhood) have improved resulting in a population of long-term survivors, albeit with limited 
knowledge of their neurocognitive function, quality of life, and adaptive function.   
 
Methods: Patients treated at The Children’s Hospital at Westmead, Sydney, Australia during 
childhood (ages 6-18), and a minimum of five years post diagnosis (n = 20) participated in a 
neuropsychological evaluation.  Demographic and tumour related variables were independently 
analyzed.  
 
Results: The majority of the participants demonstrated average ability on most cognitive tasks, 
although we found some variability resulting in three subgroups ranging from mild to severe 
functioning. The lower cognitive functioning subgroup demonstrated challenges on tasks of 
memory, processing speed, and executive function. In addition, they self-reported sub-clinical to 
clinical ranges in internalizing and externalizing symptoms as well as difficulties in physical 
health, and social and emotional well-being. Medication consumption and less education were 
moderators of biological risk. None of the tumour related factors were identified as moderators, 
in part due to the small sample size. Positive associations between challenges in adaptive 
function (internalizing and externalizing symptoms) and difficulties in perceived cognitive 
abilities and health related quality of life were identified in the sample.  
 
Conclusions: This study highlighted the variability in long-term outcomes of low-grade gliomas 
and the necessity for routine follow-up care over the course of recovery and survivorship.   
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Overview 
Brain tumours are the most common solid tumour entity in children and constitute 15-20% of all 
childhood cancers. Their incidence in childhood is approximately 3.3 per 100 000 per year 
(Kaatsch, et al.,2001).  Central nervous system tumours are particularly dangerous because of 
their proximity to vitally important structures. Brain tumours vary by location, histology, and 
pathology. They are classified based on the notion that each type of tumour results from the 
abnormal growth of a specific cell type. The cell type predicts tumour behaviour, choice of 
therapy, and prognosis. By definition, high-grade tumours expand and affect healthy tissue more 
rapidly than low-grade tumours. Low-grade tumours are usually benign and do not typically 
spread to other areas of the brain and body. About 50% of all brain tumours arise from 
supportive tissue in the brain and are collectively called gliomas. Gliomas can be differentiated 
further depending on their cell of origin. Examples of gliomas include astrocytomas, 
oligodendrogliomas, and ependymomas. Low-grade gliomas account for 51.5% of primary 
central nervous system tumours in children (Ullrich & Pomeroy, 2003).  The diagnosis is based 
on patient history, physical examination, and imaging data. Low-grade gliomas are primarily 
treated by surgery, but treatment can include adjuvant chemotherapy and focal radiation therapy. 
Survival rates in this tumour population are very favorable ranging from 50% to 95% for 5-year 
survival rates depending on the type of glioma (Cancer Research UK); thus leading to a 
population of long-term survivors of pediatric low-grade gliomas. Yet, it is unclear how this 
population fares in the long-term in terms of neurocognitive function, quality of life, and 
adaptive function.  The purpose of this dissertation was to explore these outcomes in a select 
sample of survivors of this type of brain tumour. 
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Chapter 1: Background 
 
Section 1: Theoretical models of outcomes 
A number of theoretical frameworks have contributed to the field of pediatric neuropsychology. 
Theories relevant to the brain tumour population under study were examined and guided our 
exploration of protective and vulnerability factors in the research on pediatric low-grade gliomas.  
One of the earliest models in the prediction of neuropsychological outcome, the “Kennard 
Principle” was coined by neuropsychologists based on Margaret Kennard’s work with animal 
models in the 1930s. This model suggested that greater plasticity was inversely related to 
younger age of brain insult, in that healthy tissue presumably adopted functions previously 
destined for the injured areas (Ris & Beebe, 2008). Kennard’s research on brain-behaviour 
relationships laid the groundwork for current models of developmental neuropsychology in terms 
of recovery of function and how functionality was affected in the lesioned brain.  She advanced 
the notion that brain pathology alters the developmental sequence of a skill and by studying these 
sequences we can better understand the typical trajectory for that skill. Her research proposed 
that age at lesion operated in interaction with both lesion location and behavioural task and that 
the lesion itself was a poor predictor of outcome. For example, she argued that age was more 
important for recovery of motor function than for association cortex functions, such as memory 
and executive functions. Early brain damage did not consistently spare function or optimize 
functional recovery, but could be more, less, or equally disabling than later-onset injury, 
depending on the features of the injury, post-injury neuroanatomical reorganization, the staging 
of the lesion, and how and when the outcome was assessed (Dennis, 2010).   
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Kennard’s work on brain-behaviour relationship was oversimplified and reduced to a principle 
that was later refuted by most researchers as an all-encompassing theory, yet it continues to 
plague current understanding of plasticity. Her principle is mentioned here to eradicate notions 
that the pediatric low-grade brain tumour population is free from functional damage. Studies of 
long-term effects in survivors of brain injuries gained in popularity across the field of 
developmental neuropsychology following Kennard’s theories. Our population of study, 
survivors of childhood low-grade gliomas, provides an excellent model to further understand 
brain plasticity within Kennard’s framework of the interaction between age and associated 
factors, since it involves focal insults (tumour, surgery, and focal radiation therapy) of varying 
magnitude, at varying ages, and to different regions of the brain.   
 
Kennard’s theories paved the way for modern theories of Brain Reserve Capacity (Satz, 1993) 
and Cognitive Reserve Capacity (Stern, 2002) which go beyond global statements of plasticity. 
Brain Reserve Capacity (BRC) is based on evidence of a certain degree of redundancy (in 
neurons, axons, synaptic activity) in the central nervous system, with functioning preserved until 
such time that a critical threshold of damage is reached. Cognitive Reserve Capacity (CRC) is an 
extension of this theory whereby cognitive factors (i.e., intelligence and educational level) 
further buffer protection or vulnerability.   
 
Satz’s (1993) theory of BRC was predominately drawn from the aging and dementia literature 
(i.e., Alzheimer’s and Parkinson’s diseases) to explain threshold differences in the onset of 
clinical symptoms and the expression of impaired test performance after acquired brain injury. 
Like Kennard, Satz highlighted the importance of the timing of the injury while expanding his 
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model to incorporate structural differences in the brain. His model reflected two main postulates 
of injury based on brain reserve capacity, 1) greater brain reserve capacity acts as a protective 
factor, and 2) less brain reserve capacity acts a vulnerability factor. For example, in Alzheimer’s 
disease, senile plaques and neurofibrillary tangles must exceed a quantitative threshold before 
clinical symptoms of dementia are expressed (Miller, Hicks, D’Amato, & Landis, 1984). 
Similarly, in Parkinson’s disease clinical manifestations present once a proportion of neurons in 
the nigrostriatal areas are depleted and there is reduction in dopamine receptors (Quinn, Rossor, 
& Marsden, 1986). For my dissertation, the postulate that comes from this theory is that brain 
reserve capacity in brain tumour patients can act as either a protective or a vulnerability factor.    
 
The BRC theory further included the following three sub-postulates of vulnerability which could 
alter the threshold level for symptom presentation:  the effects of aggregate lesions (i.e., the 
presence of additional lesions decreases threshold and produces functional impairment), 
temporal onset (i.e., timing of the insult could result in early or delayed onset of disease 
progression), and task challenge factor (i.e., functional impairment is demonstrated when a 
challenge is presented regardless of level of BRC).  Satz further theorized that inter-individual 
differences in brain reserve (the amount of brain tissue or neuronal loss) could alter the symptom 
threshold, and therefore alter the behavioural and neuropsychological outcomes when lesions 
were equivalent (Satz, 1993).  
 
Although the threshold models of BRC and CRC were developed to account for the inter-
individual variability in outcomes in adults, it can be extended to children with medical 
disorders, with additional qualifications. Children have less brain reserve than their adult 
5 
 
counterparts which can be accounted for by brain size and a smaller number of synaptic 
connections between still maturing neurons. As such, we would predict greater vulnerability with 
younger age of diagnosis of glioma, when exploring neuropsychological and adaptive 
functioning. Reserve may also differ according to brain region in children, whereby skill 
acquisition and skills maintenance can be affected by different patterns of injury. The temporal 
onset documented in the models would incorporate the rapidity of onset of symptoms and 
chronological age. Finally, the impact of the summation of repeated brain insults can be 
understood as depletion in brain reserve over time with repeated episodes of injury from primary 
and secondary insults, causing irreversible brain damage. Studying the long-term effects of 
pediatric low-grade tumours may help capture the full effects of early brain insult, particularly 
age-related declines in neuropsychological functioning. In addition, the current study aims to 
demonstrate inter-individual differences across the sample by investigating the sub-postulates of 
vulnerability proposed by Satz. 
 
Maureen Dennis (2000) proposed an alternative, yet similar, model to inform the relationship 
between medical disorders and outcomes in children. Her model dictated that impairment or 
cognitive phenotype was set by a predetermined biological risk (based on the medical disorder), 
which was moderated by development of the child, time since onset, and reserve (See Figure 1).  
In order to gain an appreciation for her model, the components are explained and related to the 
study when applicable. 
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Figure 1. Dennis’s model of the relationship between medical condition and cognitive phenotype 
(Yeates, Ris, & Taylor, 2000).  
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A cognitive phenotype, defined as the presentation of mental and behavioural skills, is expressed 
when development, time, and reserve are integrated. The cognitive phenotype involves five 
concepts: modal profile, variability, core deficits, challenge level, and phenocopy. The modal 
profile represents the typical presentation of cognitive strengths and weaknesses associated with 
a medical disorder. Variability in cognitive phenotype can be understood as an outcome measure. 
For example, the variability of performance over time can be indicative of a medical condition or 
the variability in a medical condition can predict variability in cognitive outcome. Core deficits 
relate to the cognitive phenotype of a medical condition, such that that represents an underlying 
cognitive impairment that is insensitive to disorder severity and intelligence.  The challenge level 
is an important element of the cognitive phenotype, whereby children with medical conditions 
may demonstrate impaired performance on neuropsychological tasks as the challenge level is 
increased such as multi-tasking or divided attention, whereas controls may demonstrate only 
subclinical performance under the same challenges. Failure in performance on low-challenge 
tasks is observable in individuals with severe medical conditions, whereas failure on high-
challenge tasks might represent individuals who appear superficially cognitively intact in daily 
activities. Lastly, cognitive phenocopies are expressions of similar cognitive phenotypes that 
arise from different underlying cognitive processes. For example, poor reading comprehension is 
seen in children with head injury and hydrocephalus, yet the first is related to processing speed 
and the latter is associated with semantic integration (Barnes, Dennis, & Wilkinson, 1999; 
Barnes, Faulkner, & Dennis, 1999). The cognitive phenotype examined in the current study 
involved the exploration of modal profile in neurocognitive, quality of life, and adaptive 
behaviour, anticipated variability within the group, and evaluated if the challenge level in the 
measures is sensitive to outcomes in this population.  
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As mentioned above, the cognitive phenotype is determined by biological risk factors, which can 
be defined by a summation of genotype, metabolism, environmental toxicity, congenital brain 
dysmorphologies, primary and secondary effects of acquired brain insult, and treatment 
comorbidity. Genotype refers to the genetic bases of a particular disorder and can account for 
some modal profiles. Metabolic disorders are relevant to childhood medical conditions which 
lead to deteriorating behaviour, dementia, severe disability, and in some cases death. 
Environmental toxicity refers to exposure of toxins to both mature and immature brains and can 
increase the risk of developmental cognitive morbidity, particularly with early exposure. Brain 
dysmorphologies capture medical conditions which affect myelination and white matter, such as 
lesions to the brain. The cognitive phenotype may be altered dependant on the type and regional 
distribution of brain abnormalities. For example, childhood acquired cerebellar lesions are 
believed to be associated with motor and cognitive dysfunctions from pediatric time of onset to 
early adulthood (Dennis, et al., 1999). Primary severity of acquired conditions is a significant 
medical risk factor, particularly for brain tumours whereby the class of tumour is dependent on 
the type and stage of cell development incurring a range of severity of mortality and morbidity. 
Secondary effects of congenital and acquired conditions can exacerbate the effects of the primary 
injury, although they can be reversed given accurate and timely treatment. For example raised 
intracranial pressure can occur secondary to medical conditions including brain tumours, altering 
the cognitive phenotype following shunt treatment (Raimondi & Tadanori, 1981). Treatment 
morbidity has the potential to treat the medical condition at the cost of functional impairment. 
For example, children with brain irradiation treatments have been shown to experience 
widespread neurocognitive deficits. Reflecting on the biological risk factors in the model, 
patients with brain tumours have the potential for genotype malformations (i.e., gene additions or 
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deletions), metabolic concerns (i.e., tumours affecting pituitary or thyroid glands), brain 
dysmorphologies (i.e., lesions in localized areas of the brain), primary and secondary effects of 
the lesion (ex. hydrocephalus, seizures, chronic medication, amongst other effects), and 
treatment comorbidity (i.e., surgery, chemo-, and radiation therapy).  Despite advances in the 
molecular biology of brain tumours, the etiology remains unknown. Recent identification and 
isolation of brain cancer stem cells (BCSCs) have led to greater understanding of the molecular 
pathogenesis and possibly the catalyst of brain tumours, suggesting the presence of BCSCs 
would contribute to biological risk (Lee et al., 2012) 
 
Unlike adult models of outcomes of medical disorders, Dennis’s model incorporated the 
development of the child, which is defined as the child’s chronological and functional age. This 
factor included the age at onset of insult (i.e., pre- or perinatal, early childhood, and late 
childhood), the course of skill development, mastery and maintenance, and the potential for age 
related skill decline. In childhood-onset disorders, children have the additional tasks of meeting 
developmental challenges in addition to the demands of recovery.  As such, the cognitive 
phenotype is an expression of how the biological risk is moderated by previously acquired skills 
and the acquisition of new skills. Differentiating between previously acquired skills and the 
acquisition of new skills can be accomplished from longitudinal studies; nonetheless cross-
sectional studies such as the current study offer the opportunity to review the following factors: 
age at insult, comparison of skill development to normative standards, and hypothesizing 
potential age related decline.   
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Dennis’s model also accounted for time since onset of medical disorder, with the notion that time 
is not ubiquitous with recovery. In fact, cognitive deficits can emerge with time particularly with 
children, whereby a disorder can result in a slower rate of skill acquisition over time and residual 
deficits following recovery. This pattern has been documented among young head-injured 
children compared to older children with equally severe injuries (Anderson & Moore, 1995). The 
effects of time since onset on cognitive phenotype are best captured by studies of adult survivors 
of childhood medical disorders, such as in the design of the current study. Longitudinal studies 
that follow a cohort of children are particularly valuable such that they reveal cognitive 
morbidity of a childhood medical disorder and the developmental trajectories in children with 
varying medical severities and biological risk. Nonetheless, comparisons through cross-sectional 
studies offer valuable information to determine whether the cognitive phenotype is related to a 
slower rate of skill acquisition or a deficit.   
 
Dennis’s model incorporated reserve as a moderator of biological risk much like the BRC and 
CRC theories, although reserve in her model  has been expanded to include the child’s 
demographics, family, and social context of peers and school. Demographic variables, such as 
sex and socio-economic status, address pre-insult status and can influence outcomes and in some 
cases increase the risk of the medical disorder. Post-insult status is additionally relevant; in that a 
child’s physical and mental health following injury can moderate outcome severity. Finally, the 
child’s social context can ameliorate treatment compliance or hinder recovery. The current study 
aimed to address demographic variables of the survivor including sex and educational 
attainment, and investigates cognitive function, quality of life, and adaptive function as outcome 
measures.  
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A child’s cognitive phenotype or outcome is in essence much more complicated than simply 
knowing the acquired medical condition. Each of the factors presented above can be plotted into 
an outcome algorithm for children. Similar to the adult threshold model, there exists a variable or 
“floating” threshold for impairment in which function can be buffered or exposed dependent on 
level of biological risk, development, time, and reserve. Figure 2 depicts a sketch of this outcome 
algorithm, which provides an extension of the model that Dennis proposed, as outlined above.  
 
The first postulate suggests that children with high biological risk experience at least subclinical 
impairment on tasks of high challenge regardless of development, time, and reserve, whereas 
children with low biological risk will present with neither subclinical nor clinical impairment. 
The second postulate relates to the impact of the moderators of development, time, and reserve 
on biological risk. Each of the moderators is provided with positive or negative values dependent 
on whether it exacerbates or buffers the cognitive phenotype, respectively. Moderators with no 
impact on cognitive phenotype take a zero value. Positive values place children with high 
biological risk in the impairment range, whereas negative values have the potential to shift them 
from the impairment range. Children with low biological risk can tolerate modest levels of 
positive values in development, time, and reserve without shifting them into the impairment 
range due to a buffer zone. The final postulate suggests that factors of development, time, and 
reserve are not necessarily additive or equivalent in nature. Instead, they operate differently for 
children at different levels of biological risk and medical conditions.  In this study, I adopted this 
theoretical framework to conceptualize our findings of neurocognitive, quality of life, and 
adaptive functioning. 
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Figure 2. Hypothetical model of the outcome algorithm for children with high and low biological 
risk. Development of the child, time since onset, and reserve moderate the effects of biological 
risk shifting the impairment threshold either towards impairment or free from impairment 
(Yeates, Ris, & Taylor, 2000).
LOW CHALLENGE TASK 
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The question in the current study was whether we can determine whether there are high or 
low levels of risk, based on the cognitive phenotypes. This knowledge would then lead to an 
exploration of outcomes of adaptive functioning and neuropsychological functioning based on 
factors such as time since diagnosis of glioma, demographic factors, and tumour variables. 
What follows is a discussion of the existing literature on pediatric gliomas, what factors we 
know might affect cognitive and adaptive outcomes, and gaps in the research that will be 
addressed by my findings. 
 
Section 2: Impairments in neurocognitive outcomes 
Brain tumours in children are known to cause varying cognitive deficits. However, the pattern 
that emerges is unclear due to disease related factors such as the origin of the tumour, the cell 
type, the tumour location, the malignancy grade, and the type of treatment. Different types of 
tumours have the propensity to affect the brain in many ways resulting in different 
neuropsychological patterns of dysfunction. The outcomes of neuropsychological tests have 
not been widely studied for the low-grade glioma pediatric population and limited research 
has been acquired for long-term effects. Our study aims to fill this gap in the literature.   
 
Due to the limited knowledge base of research on low-grade gliomas, exploration of both the 
adult and pediatric literature is required, with a cautionary note that patients may vary due to 
developmental processes and their interaction; including biological, cognitive, and 
socioemotional factors. As an example, the adult literature has shown conflicting results on 
the impact of tumour localization and cognitive deficits, with either no significant correlations 
(Mulhern, Kovnar, Kun, Crisco, and Williams 1988), specific deficits of verbal memory 
(Surma-aho et al., 2001; Taphoorn et al., 1994), or widespread impairment related to tumour 
localization (Taphoorn et al., 1992).   Long-term studies of children with posterior fossa 
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tumours have revealed deficits in perceptual-motor skills, visual memory, verbal fluency, and 
executive functioning (Steinlin, et al, 2003). Similarly, Aarsen and colleagues (2004) found a 
combination of long-term impairments in language, sustained attention, visual-spatial, 
executive function, and memory problems in children with cerebellar astrocytomas. These 
studies document a pattern of memory and executive dysfunction that exists amongst the low-
grade glioma tumour patients irrespective of tumour location. 
 
Research on the effect of treatment type on neurocognitive outcomes has shown mixed 
results. Cross-sectional studies evaluating IQ scores of pediatric brain tumour patients, in 
particular medulloblastomas, have found decreases in IQ scores following radiation treatment. 
Age at diagnosis and radiation dose moderated the effect of the cognitive decline (Palmer et 
al., 2001; Radcliffe et al., 1994), with greater deficits at higher doses of radiation and at a 
younger age at diagnosis. It has been suggested that these deficits are a result of an inability to 
acquire new information at an age appropriate rate rather than a loss of previously learned 
information (Palmer et al., 2001). Taphoorn and colleagues (1994) demonstrated disturbances 
in cognitive and affective measures for adult patients with low-grade gliomas with no 
significant differences between treatment types.  Treatment type may play a role in patients’ 
quality of life outcomes in addition to neuropsychological outcomes. 
 
Studies have revealed cognitive and behavioural difficulties for children who undergo surgery 
alone for treatment of brain tumours (Beebe et al., 2005; Levisohn, Cronin-Golomb, & 
Schmahmann, 2000; Meyer & Kieran, 2002). For example, Levisohn and colleagues (2000) 
studied children treated with surgery alone for cerebellar tumour in the first two years after 
surgery and found difficulties in executive functioning, visual-spatial functioning, verbal 
memory, and dysregulation of affect. In addition, greater behavioural deficits were noted in 
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older participants compared to younger ones. Similarly, Beebe and colleagues (2005) found 
declines in Full Scale IQ, spelling, and adaptive functioning in a pediatric sample of children 
with low-grade cerebellar tumours. Changes at twelve months post treatment were reported in 
a separate sample of pediatric brain tumour survivors, whereby declines in intellectual 
functioning and moderately elevated behaviour problems irrespective of the treatment 
modality (surgery or radiation/chemotherapy) were reported (Taylor et al., 2007).  
Heterogeneous tumour population groups were used in these studies, which raises questions 
about the generalizability of results and the importance of either tumour type or tumour 
location.  
 
Section 3: Impairments in Quality of Life 
Research on the quality of life of brain tumour survivors has increased within the past decade 
due to high survival rates and more localized treatment methods. Taphoorn and colleagues 
(1992) established the need to evaluate both objective and subjective indices when assessing 
quality of life. They studied adults treated for low-grade gliomas and found cognitive and 
affective disturbances that were not in line with the patients’ self-report measures.  A study by 
Klein and colleagues (2003) assessed both cognitive functioning and health related quality of 
life in patients with epilepsy following low-grade glioma treatment. They studied the effects 
of epilepsy and antiepileptic drug treatment on cognitive functioning and health related 
quality of life in an adult population. They found significant reductions in information 
processing speed, psychomotor function, attention, verbal and working memory, executive 
function and health related quality of life. The cognitive reductions were primarily attributed 
to the use of anti-epileptic drugs for most of the domains, whereas quality of life was 
attributed to the lack of complete seizure control. This study highlights the need to address 
disease related factors, such as seizure medication, as moderators of outcome. In addition, 
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these studies demonstrate the need to pair neurocognitive measures with quality of life 
measures when assessing patient outcomes. 
 
In a long-term follow up study of survivors of childhood brain tumours compared to their 
siblings, the brain tumour survivors were more likely to have cognitive disturbances, be 
unemployed or unmarried, and to have visual or auditory disturbances. In addition, the tumour 
group was more likely to die in early adulthood of other causes (Mostow et al., 1991). To 
note, this study included a mixed sample of central nervous system tumour survivors 
suggesting possible divergence in outcomes with our low-grade tumour study group. In a 
separate study of various cancer survivors, adolescents were shown to be at a risk for poor 
health related quality of life, whereas preschoolers were at risk for behaviour problems 
(Barrera et al., 2003). These results demonstrate adjustment issues through development and 
in the long term, although it is unknown if similar findings are revealed in the low-grade 
glioma populations.  As such, the current study fills a gap in understanding the quality of life 
outcomes in survivors of pediatric low-grade glioma.   
 
Reports of long-term neurocognitive and behavioural impairments related to low-grade brain 
tumours are limited and inconsistent in the pediatric literature. Studies with brain tumour 
patients have included children and adults with varying diagnoses, malignancies, and duration 
of recovery.  Thus, identifying parallel findings across the research is problematic and there is 
a lack of specificity for the pediatric population of interest. Nonetheless, results from previous 
studies provide valuable information for test design and implementation.   
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Chapter 2: Research Objectives and Predictions 
 
Purpose 
The purpose of the study was to explore the long-term outcomes of patients diagnosed with 
low-grade gliomas in childhood and adolescence, in particular neuropsychological profiles 
and patterns, perceived quality of life, and adaptive functioning.  It is believed that the low-
grade glioma brain tumour population has the best survivorship and outcomes, albeit with 
little research to support the latter notion. The present study included only this subgroup of 
tumour patients allowing for a more detailed investigation of tumour related factors (e.g., 
tumour location, tumour pathology, treatment type), and demographic factors. The sample 
data were compared to age-standardized normative data for each measure. Some of the 
measures chosen were adopted in previous research demonstrating significant results in 
patients during the acute phase of recovery (within twelve months from treatment). Other 
measures with sound psychometric data were included to add breadth and depth to the current 
exploration.  This study was exploratory in nature; therefore, did not use traditional 
hypothesis testing. However, in the spirit of transparency, presuppositions concerning the 
various types of differences we expected to find are listed below. We anticipated that results 
of this study would augment and generate new knowledge of long-term effects for patients 
with low-grade gliomas, with a goal of assisting in the proactive management of daily living. 
Finally, the findings were expected to provide a source of information for children undergoing 
treatment for low-grade gliomas and their families. The objectives are listed below.  
 
Part A: Neuropsychological profile 
1. Explore heterogeneity in the sample population’s neuropsychological scores. 
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a. It was expected that a post-hoc analysis would reveal subgroups of patients 
based on the number of neurocognitive measures scored below 1 standard 
deviation. 
2. Explore the inter-group variation on all neurocognitive measures.  
a. It was expected that different subgroups (based on objective 1) would perform 
differently on measures of attention, memory, visuospatial, processing speed, 
motor, and executive function. It is hypothesized that those with more severe 
general impairments would show greater impairments in each of these 
domains. 
3. Explore differences in neuropsychological scores based on demographic variables. 
a. It was expected that differences would exist based on education, age at 
diagnosis, and medication use, and not on sex. Based on extant literature, we 
expected to find that: 
i. Men and women with low-grade glioma would perform equivalently on 
all neuropsychological measures.  
ii. Those with lower education would perform worse than those with 
higher education on neuropsychological measures. 
iii. Those with a younger age at diagnosis would perform worse than those 
with an older age at diagnosis on all neuropsychological measures. 
iv. Those with greater medication use would perform worse than those 
with less medication use on all neuropsychological measures. 
4. Explore differences in neuropsychological scores based on tumour related factors. 
a. It was expected that differences would exist based on the type of tumour, 
tumour location, treatment method, and secondary tumour related symptoms.  
Based on extant literature, we expected to find that: 
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i. Those with astrocytomas would outperform those with other types of 
tumours.   
ii. Those with cerebellar tumours would have fewer cognitive difficulties 
than those with tumours in other areas.  
iii. Those who underwent adjuvant therapy, such as chemotherapy or 
radiation therapy would have more difficulties in attention and 
executive functions than those with surgery alone.  
iv. Those with secondary symptoms such as seizures or hydrocephalus 
would have more cognitive difficulties than those with no secondary 
symptoms.  
 
Part B: Perceived Quality of Life (QoL) 
1. Identify domains of strength and weakness in the sample population’s perceived 
health and cognitive quality of life.   
2. Explore the inter-group variation in the quality of life questionnaires.  
a. When groups derived for Part A: objective 1 are compared on quality of life 
outcomes, those with more severe neuropsychological outcomes will express a 
poorer quality of life. 
3. Explore differences in perceived quality of life scores based on demographic 
variables.  
a. It was expected that men and women with low-grade gliomas would perform 
equivalently on perceived QoL measures.  
b. It was hypothesized that those with lower education would show poorer scores 
on QoL variables. 
c. It was expected that poorer QoL for those with younger age of diagnosis. 
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d. It was expected that poorer QoL for those with higher medication use. 
4. Explore differences in perceived quality of life scores based on tumour related factors. 
a. Because of a lack of extant literature, no hypotheses were specified; however, 
exploratory analyses on QoL were conducted for tumour location, type of 
tumour, treatment type, and tumour-related symptoms.  
5. Explore relationships between perceived health and cognitive related quality of life 
scores. 
a. It was expected that there would be significant positive correlations between 
perceived health and QoL ratings. 
6. Explore relationships between perceived cognitive related quality of life scores and 
measures of intelligence. 
a. It was expected that there would be significant positive correlations between 
intelligence, and QoL. 
 
Part C: Psychological adaptation 
1. Identify domains of strength and weakness in the sample population’s adaptive 
functioning. 
2. Explore the inter-group variation across the adaptive measures.  
a. When groups derived for Part A are compared on quality of life outcomes, 
those with more severe neuropsychological outcomes will express poorer 
adaptive functioning. 
3. Explore differences in adaptive scores based on demographic variables.  
a. It was expected that there would be no difference in overall adaptive 
functioning between men and women with glioma. 
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b. It was hypothesized that those with lower education would show poorer scores 
on adaptive functioning 
c. It was expected that poorer adaptive functioning for those with younger age of 
diagnosis 
d. It was expected that poorer adaptive functioning for those with higher 
medication use. 
4. Explore differences in psychological adaptive functioning based on tumour related 
factors.  
a. Because of a lack of extant literature, no hypotheses were specified; however, 
exploratory analyses on adaptive functioning were conducted for tumour 
location, type of tumour, treatment type, and tumour-related symptoms.  
5. Explore relationships between adaptive functioning and perceived health and 
cognitive related quality of life scores. 
a. It was expected that there would be significant positive correlations between 
perceived health and adaptive functioning ratings. 
6. Explore relationships between adaptive function and measures of intelligence. 
a. It was expected that there would be significant positive correlations between 
intelligence, and adaptive functioning. 
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Chapter 3: Methods and Measures 
 
Participants 
Participants were recruited from the medical records database from the Children’s Hospital at 
Westmead, New South Wales, Australia, exploring diagnoses from 1980 to 2003. The 
following inclusion criteria were required for participation: a diagnosis of tumour grade I or II 
(World Health Organization grading), diagnosis made between ages 6 to 18, and a minimum 
of 5 years since diagnosis. The exclusion criteria included a pre-tumour history of a 
developmental delay, a previous neurologic insult, and a previous diagnosis of tuberosclerosis 
or neurofibromatosis.  
 
Based on past research in the field of pediatric oncology and the limited participant pool, we 
had projected to test between twenty and twenty-five patients. Twenty patients were recruited 
and administered the full testing battery from a list of 72 patients, after applying the inclusion 
and exclusion criteria. Of those initial 72 patients, 6 had either passed away or were ill (i.e., 
recent stroke), 11 patients were not interested due to time commitments and travel distance, 
21 patients had changed their contact information from the time they were at Westmead 
Hospital, and 14 more patients had no available contact information. Tables 1 and 2 present 
the demographic characteristics of the resulting sample, as well as the tumour location and 
pathology, respectively. All participants were above age eighteen at the time of testing, as 
such only adult measures were used. Written consent and verbal assent were obtained from 
each participant prior to testing. Following the assessment, each participant received a brief 
neuropsychological report outlining their test results, including strengths and weaknesses.   
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Table 1. Demographic characteristics of the sample (n = 20) 
 
Demographics M   (SD) 
 
Age at diagnosis in years;  
 
 
11.0 (2.6) 
 
Age at testing in years;    
 
 
25.6 (4.9)  
 
Sex 
 
 
F  = 8 
 
M = 12  
 
 
Table 2. Tumour pathology and location 
 
 
 
 
Number of Participants 
 
Tumour pathology   
  Gliomas   
    Astrocytomas 17  
    Ependymoma 1  
    Oligodendroglioma 1  
    Ganglioglioma 1  
 
Tumour location 
  
    Infratentorial 11  
    Supratentorial 9  
 
 
Procedure 
Each participant was assessed using a standardized battery to test intelligence, memory, 
visual-spatial skills, motor functioning, attention, executive functioning, and processing 
speed. A demographic questionnaire and three self-report questionnaires of current adaptive 
functioning and perceived quality of life were completed by all participants. Measures were 
chosen that either spanned the potential age ranges of the participants, or that had equivalent 
child and adult measures. Table 3 lists the neuropsychological tests and questionnaires 
administered. The full battery was provided to each participant, although incomplete data 
resulted either due to either assessor or participant error (See Appendix A for the sample size 
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for each measure). Testing of each participant occurred on a single day at the Children’s 
Hospital at Westmead (by this writer) and was on average four to five hours in length. 
Medical records were reviewed for pre-, peri-, and post-operative symptoms, medications, 
and tumour-related variables.  
 
 
Table 3. List of neuropsychological tests and questionnaires by domain  
 
Domain 
 
Test 
 
Intelligence 
 
Wechsler Abbreviated Scale of Intelligence (WASI) 
 
Memory 
 
Rey-Osterrieth Complex Figure Test with delay (ROCF-delayed 
recall) 
 Rey-Auditory Verbal Learning test with delay (RAVLT) 
 Digit Span from the Wechsler Intelligence Scale for Children 
(WISC) or the Wechsler Adult Intelligence Scale (WAIS) 
 
Visual Spatial 
 
Judgment of line orientation (JOLO) 
 
Motor 
 
Purdue Pegboard  
 
Executive Skills 
 
Symbol digit modalities 
 Trail Making Test 
 Wisconsin Card Sorting Test (WCST) 
 D-KEFS: Verbal fluency, Trail making  
 Rey-Osterrieth Complex Figure Test 
 
Processing Speed 
 
Symbol Digit Modalities 
 
Quality of Life 
 
RAND-36 
 FACT-Cog 
 
Adaptive function 
 
Adult Self Report (ASR/18-59) 
  
 
 
The order of test administration was as follows: WASI, Digit Span, Purdue Pegboard, Rey-O 
Copy, Rey-O immediate recall (3 minutes), DKEFS verbal fluency, Rey-O recall, Rey-O 
recognition (30 minutes), WCST computerized task, Symbol Digit Modalities, DKEFS trail 
making test, RAVLT, RAVLT delay recall (20 minutes), RAVLT recognition (20 minutes), 
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and Judgment of  line orientation.  The questionnaires were filled out during breaks in testing 
and at the end of the test battery.  
 
 
Design 
 
The selected neuropsychological and behavioural tests used were based on age-standardized 
normative samples, thus a normative population was not necessary.   
 
The following is a list of independent demographic and tumour related variables and their 
associated levels: sex (2 levels; men, women), education (2 levels; High School Diploma/No 
High School Diploma vs. Post-High School education), age at diagnosis by development (2 
levels; 6-11 vs. 12-18 years old), age at diagnosis by puberty onset (2 levels; < 10 vs. >10 
years old), time elapsed between diagnosis and neuropsychological testing (5-15 vs. 15 + 
years), medication consumption at time of testing (2 levels; consumption vs. no 
consumption), tumour location (2 levels; infratentorial vs. supratentorial), tumour pathology 
(2 levels; astrocytoma vs. other gliomas, treatment type (2 levels; surgery vs. surgery with 
chemotherapy or radiation therapy), and symptoms at time of diagnoses (2 levels; 
hydrocephalus/seizures vs. no symptoms). 
 
The dependent variables included the neurocognitive performance, perceived quality of life, 
and adaptive outcomes.  Table 4 lists each of the outcome measures by domain. 
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Table 4. List of outcome measures by domain  
 
Domain 
 
Outcome Measures 
Intelligence Verbal IQ, Performance IQ, Full Scale IQ 
Memory Immediate recall, delayed, recognition  
Visual Spatial Orientation, copy 
Motor Limb dexterity 
Executive Skills Sequencing, problem solving, perseveration, errors in task, fluency  
Processing Speed Oral, written speed  
Quality of Life Physical function, emotional well-being, social function, general 
health, perceived cognitive impairment, perceived cognitive 
abilities 
Adaptive Function Mean adaptive, Personal strengths, Internalizing, Externalizing, 
and Total Problems scales 
  
 
 
Statistical Analyses 
 
Statistical analyses were computed with the Statistical Package for the Social Sciences (SPSS 
version 23.0 for Windows).  Given our small sample size (i.e., fewer than 30 participants) the 
available statistical analyses included comparison of means, comparing proportions using chi-
square tests, exploring confidence intervals around the mean to determine how often a result 
occurs in the sample, maximum likelihood estimator, analysis of variances (ANOVA), t –tests 
for dependent samples, and repeated measures ANOVA. In order to address our research 
inquiry interests the following analyses were conducted: 1) Frequency distributions were 
reviewed to describe the distribution of the data to determine strengths and weaknesses in the 
quality of life and adaptive measures, 2) One-way analysis of variance were adopted to 
determine inter-group differences in neuropsychological, perceived quality of life and 
adaptive functioning, 3) Repeated measures analysis of variance were run to explore 
differences between domains of perceived health related quality of life, 4)  t-tests were used to 
explore differences in demographic and tumour related factors for neuropsychological, quality 
of life and adaptive measures, and 5) correlations were performed to explore relationships 
between questionnaires and between objective and subjective measures of cognitive function.   
27 
 
Chapter 4: Results 
 
Part A: Neuropsychological profile 
 
Inquiry 1. Explore if differences exist in the sample population’s    
neuropsychological scores. 
 
In line with current neuropsychological research that suggests groups can be created post hoc 
in exploratory studies, I explored the z-scores for each of the neuropsychological measures. 
Ek and colleagues (2005) suggest that group assignment can be based on the number of 
neuropsychological tests with scores at -1 (minus one) z-scores and below. A pattern of 
variation emerged whereby we found three groups of participants based on a count of the 
number of scores below 1 standard deviation (SD) from a total of 33 outcome measure scores. 
The first group of participants, termed “Severe Dysfunction” had 11 or more scores below 1 
SD. The second group, termed “Moderate Dysfunction” had between 5 to 10 scores below 1 
SD. And the final group, termed “Mild Dysfunction” had up to 4 scores below 1 SD.  Please 
see Table 5 for group assignment. This information was then used for subsequent analyses of 
the data for the remaining inquiries. 
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Table 5. Participants grouped by level of dysfunction based on the number of measures below 1 standard deviation.  
 
 
                          SDMT                           WASI            WAIS-3   RCFT                              RAVLT                                                          Purdue 
Case Group Written Oral vIQ pIQ F4 DS Imm. Delay Reco
g 
I I-V 30min RecogA BCT P. 
hand 
NonP. 
hand 
Both 
hand 
Assm JOLO  
 
Group 1. Severe Dysfunction: 10 or more of the measures 
1. 1 - - - + - + - - + - - - + + - - - - +  
4. 1 - - + + + + + + ++ - - + - + - - - + -  
11. 1 - - - + - + - - - - - - - * * * * * *  
12. 1 - - + + + - - - - - - - - - - - - - -  
14. 1 + + - + - - - - + - - - + - - + - - +  
16. 1 - - - - - - - - - - - - - + - - - - -  
 SUM 5/6 5/6 4/6 1/6 4/6 3/6 5/6 5/6 3/6 6/6 6/6 5/6 5/6 2/5 5/5 4/5 5/5 4/5 3/5  
 
Group 2. Moderate Dysfunction: 5 to 10 of the measures 
2. 2 + + + + + + - - - - - - - + + - - - +  
5. 2 * - + ++ ++ + + ++ + ++ ++ ++ + ++ - - - - *  
8. 2 + + + + + + - + + - - - - - + - - - +  
13. 2 + + + + + + - - - + + - - + - - - - +  
15. 2 ++ + + ++ + + + + - + + + - ++ + - + - +  
17. 2 - - + + + + + ++ ++ - + ++ + + + + - - +  
20. 2 + + + + + - + + ++ - - + - * + + + - +  
 SUM 1/6 2/7 0/7 0/7 0/7 1/7 3/7 2/7 3/7 4/7 3/7 3/7 5/7 1/6 2/7 4/7 5/7 7/7 0/6  
 
Group 3. Mild Dysfunction: up to 4 measures 
3. 3 + + ++ ++ ++ + + + - + + + + + - + - - +  
6. 3 ++ ++ + ++ ++ ++ + + + ++ ++ ++ + ++ + + + - +  
7. 3 + + + ++ + + + + + + + - + + + + ++ + +  
9. 3 + + ++ ++ ++ ++ + + + + ++ ++ + ++ - + + - +  
10. 3 + + ++ ++ ++ + + + + + + + + + + ++ + + +  
18. 3 + + - + + + + - + + * * * * * * * * *  
19. 3 ++ ++ + + + ++ + + + - ++ ++ + * + + + - +  
 SUM 0/7 0/7 1/7 0/7 0/7 0/7 0/7 1/7 1/7 1/7 0/6 1/6 0/6 0/6 2/7 0/6 1/6 4/6 0/6  
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           DKEFS                                                                                                                                                   WCST 
Case Group FAS Cat. Sw_acc Sw_tot TMT_1 TMT_2 TMT_3 TMT_4 TMT_5 Tot.error P. 
resp. 
P..errors. NonP 
erorrs. 
Conc. 
Resp. 
Educ. 
 
Group 1. Severe Dysfunction: 10 or more of the measures 
1. 1 - - + - - + + + - + + + + + No HSD 
4. 1 + + + - + + + - + ++ ++ ++ + + HSD 
11. 1 * * * * * * * * * - + + - - HSD 
12. 1 - - + - - - - + + - + + - - PostHSD 
14. 1 - - + + + + + - + + + + + + No HSD 
16. 1 - - - - - - * * - - - - - - No HSD 
                 
 
Group 2. Moderate Dysfunction: 5 to 10 of the measures 
2. 2 + ++ + + + + + + + + + + + + PostHSD  
5. 2 ++ ++ ++ ++ - - * * * + + + + + PostHSD 
8. 2 * * * * + ++ ++ + + ++ + + ++ ++ PostHSD 
13. 2 + + + + + + + + + + + + + + PostHSD 
15. 2 + + + + + + + + + - - - - - HSD 
17. 2 + ++ ++ ++ + + + + + + + + + + PostHSD 
20. 2 - + + + + + + + + + + + - + No HSD 
                 
 
Group 3. Mild Dysfunction: up to 4 measures 
3. 3 + ++ + + + + + + + + + + + + PostHSD 
6. 3 ++ ++ + + + ++ ++ + + + + + + + PostHSD 
7. 3 + ++ ++ ++ + + + + + + + + + + PostHSD 
9. 3 ++ + + + + + + + + + + + + + PostHSD 
10. 3 ++ ++ + + + + + + + + + + + + PostHSD 
18. 3 - + + + * * * * * + + + + + PostHSD 
19. 3 ++ ++ ++ ++ + + + ++ + + + + + + HSD 
                 
                 
Note: ++ = above 1 standard deviation, + =  within -1 and 1 standard deviation- = less than -1 standard deviation, and * = missing data. 
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Inquiry 2. Explore the inter-group variation on all neurocognitive measures.  
 
 Analysis of Variance. 
A series of analyses of variance were conducted across all dependent measures of 
neurocognitive functioning for each of the three aforementioned groups outlined above 
(“Severe Dysfunction”, “Moderate Dysfunction”, and “Mild Dysfunction”). Descriptive 
statistics for each neurocognitive measure by level of dysfunction are presented in Appendix 
B.  [The Bonferroni correction was used to identify significant effects (i.e., p =.05/10 = 
0.005).] Because the analyses were exploratory, results at the 0.05 level will also be 
described. 
 
 Post-Hoc Contrast Analyses.  
In order to determine the group differences between the levels of impairment, a series of post-
hoc contrast analyses was conducted (Severe dysfunction vs. Moderate dysfunction; Severe 
dysfunction vs. Mild dysfunction; and Moderate dysfunction vs. Mild dysfunction). Post hoc 
comparisons using the Tukey HSD were obtained when measures of equal variances were 
assumed and the Dunnett T3 for the measures where equal variances were not assumed. 
Analyses of variance revealed significant differences between groups in the following 
domains: Intelligence, Memory, Processing Speed, and Executive skills. 
 
Intelligence 
Analyses of variances revealed a significant main effect of group on the WASI Full Scale IQ 
(F(2,17) = 13.91, p = .000), WASI Verbal IQ (F(2,17) =  11.99, p = .001), and WASI 
Performance IQ (F(2,17) = 10.24, p = .001).   Post-hoc comparisons across all three measures 
of intelligence revealed that the mean z-score for the Severe Dysfunction group was 
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significantly lower than the Moderate and Mild Dysfunction groups. No differences between 
the Moderate and Mild groups were found.  The results are presented in Table 6.  
 
Table 6. Analyses of variance of measures of intelligence by level of dysfunction 
 
 
IQ Measure 
Level of Dysfunction  
F 
 
η2 Severe Moderate  Mild  
 
WASI- Full Scale IQ 
 
-1.22a 
 
.63 b 
 
1.11 b 
 
13.91** 
 
.62 
 (1.01) (.49) (.92)   
 
WASI- Verbal IQ 
 
-1.44 a 
 
.19 b 
 
.82 b 
 
11.99** 
 
.58 
 (1.04) (.43) (.97)   
 
WASI- Performance IQ 
 
-.72 a 
 
.84 b 
 
1.20 b 
 
10.24** 
 
.54 
 (1.04) (.62) (.73)   
      
Note. * = p ≤ .005, ** = p ≤ .001. Standard deviations appear in the parentheses below the 
means (reported as z-scores). Means with differing subscripts within rows are significantly 
different at the p ≤ .05 based on Tukey’s HSD post hoc comparisons.  
 
 
Memory 
Analyses of variances revealed a significant main effect of group on the RCFT immediate 
recall (F(2,17) = 9.01, p = .001), and the RAVLT total recall measures(F(2,16) = 12.95, p = 
.000).    Post-hoc comparisons (Dunnett T3) on the RCFT immediate recall demonstrated that 
the mean z-score for the Severe Dysfunction group was significantly lower than the Mild 
Dysfunction group and not the Moderate Dysfunction group. No differences were found 
between the Moderate and Mild groups. Post hoc comparisons (Tukey HSD) on the RAVLT 
total recall measure revealed that the mean z-score for the Severe Dysfunction group was 
significantly lower than the Moderate and Mild Dysfunction groups. The results are presented 
in Table 7. 
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Table 7. Analyses of variance of measures of memory by level of dysfunction 
 
 
Memory 
Level of Dysfunction  
F 
 
η2 Severe Moderate Mild 
 
RCFT- immediate recall 
 
-2.16a 
 
-.67a 
 
.17 b 
 
9.01** 
 
.55 
 (1.01) (.49) (.92)   
 
RAVLT- total recall 
 
-2.92 a 
 
-.57b 
 
.65 b 
 
12.95** 
 
.61 
 (1.46) (1.22) (.98)   
      
Note. * = p ≤ .005, ** = p ≤ .001. Standard deviations appear in the parentheses below the 
means (reported as z-scores). Means with differing subscripts within rows are significantly 
different at the p ≤ .05 based on Dunnet T3 (RCFT) and Tukey’s HSD (RAVLT) post hoc 
comparisons.  
 
 
Processing Speed 
 
Analyses of variance revealed a significant main effect of group on the SDMT written 
(F(2,16) = 9.67, p = .002), and oral measures (F(2,17) = 9.91, p = .001).   Post hoc 
comparisons (Tukey HSD) on the SDMT written measure revealed that the mean z-score for 
the Severe Dysfunction group was significantly lower than the Moderate and Mild 
Dysfunction groups. Post-hoc comparisons on the SDMT oral measure revealed that the mean 
z- score for the Severe Dysfunction group was significantly lower than the Mild group alone. 
The results are presented in Table 8.   
 
Table 8. Analyses of variance of measures of processing speed by level of dysfunction 
 
 
Processing Speed  
Level of Dysfunction  
F 
 
η2 Severe Moderate Mild 
 
SDMT- written  
 
-3.15a 
 
-.14 b 
 
.78 b 
 
9.67** 
 
.54 
 (2.13) (1.23) (1.51)   
 
SDMT- oral 
 
-2.45 a 
 
-.50a 
 
.85 b 
 
9.91** 
 
.53 
 (1.50) (1.28) (1.25)   
      
Note. * = p ≤ .005, ** = p ≤ .001. Standard deviations appear in the parentheses below the 
means (reported as z-scores). Means with differing subscripts within rows are significantly 
different at the p ≤ .05 based on Tukey’s HSD post hoc comparisons.  
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Executive Functioning 
Analyses of variance revealed a significant main effect of group on the DKEFS TMT number-
letter switch (F(2,13) = 13.81, p = .001), measure and the DKEFS verbal fluency category 
switching measure (F(2,15) = 8.40, p = .004).   Post hoc comparisons (Tukey HSD) on the 
both measures of executive functioning revealed that the mean z-score for the Severe 
Dysfunction group was significantly lower than the Moderate and Mild Dysfunction groups. 
The results are presented in Table 9.   
 
Table 9.Analyses of variance of measures of executive function by level of dysfunction 
 
 
Executive Function 
Level of Dysfunction  
F 
 
η2 Severe Moderate Mild 
 
DKEFS TMT- number letter switch 
 
-.91a 
 
.22 b 
 
.66 b 
 
13.81** 
 
.68 
 (.57) (.49) (.36)   
 
DKEFS verbal fluency switch- total 
 
-1.20 a 
 
.33b 
 
.99b 
 
8.40** 
 
.52 
 (1.06) (.96) (.77)   
      
Note. * = p ≤ .005, ** = p ≤ .001. Standard deviations appear in the parentheses below the 
means (reported as z-scores). Means with differing subscripts within rows are significantly 
different at the p ≤ .05 based on Tukey’s HSD post hoc comparisons.  
 
 
Inquiry 3. Explore differences in neuropsychological scores based on 
demographic and disease variables.  
 
 Independent t-tests. 
A series of independent t-tests was conducted across all dependent measures of 
neurocognitive functioning for sex, education, age at diagnosis, medication consumption at 
time of testing, and time elapsed between testing and diagnosis. Analyses were not conducted 
by level of dysfunction since too few patients were included in each subgroup. See Appendix 
C for demographic data by level of dysfunction.   
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Sex 
Comparisons between men (n = 12) and women (n = 8) demonstrated no significant 
differences across all neuropsychological variables.  
 
Education 
Groups were created based on participants’ level of education (No high school diploma; n = 4, 
High school diploma; n = 4, and Post high school education; n = 12). The groups No High 
school diploma and High school diploma were combined due to small sample sizes per group. 
Differences between levels of education were found on all the intelligence quotients (Full 
Scale IQ; (t(18) = -3.396, p = .003), Verbal IQ; (t(18) = -3.386, p = .003), and Performance 
IQ; (t(18) = -2.517, p = .022) such that those with post-high school education had superior 
performance compared to those with the high school or below combined group. See Table 10 
for statistical data.  
 
Table 10. Comparison of measures of IQ between levels of education 
 
Intelligence Quotients 
Education  
T 
 
df No High School Diploma/ 
High School Diploma 
 
Post High School 
education 
 
WASI Full Scale IQ 
 
-.70 
 
.88 
 
-3.39** 
 
18 
 (1.29) (.80)   
 
WASI Verbal IQ 
 
-1.08 
 
.54 
 
-3.38** 
 
18 
 (1.25) (.80)   
 
WASI Performance IQ 
 
-.18 
 
1.32 
 
-2.51* 
 
18 
 (.95) .71   
     
Note. * = p ≤ .05, ** = p ≤ .005. Standard deviations appear in the parentheses below the 
means (reported as z-scores).  
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Age at diagnosis 
Age at diagnosis was defined categorically in two dimensions, by developmental age 6-11 (n 
= 12 ) versus 12-18 (n = 8), and by puberty onset at diagnosis (<10 years of age n = 10 and 
>10 years of age n = 10). Comparisons for age at diagnosis by development revealed no 
significant differences across the neuropsychological measures. Age by puberty onset at the 
time of diagnosis revealed differences in the following domains: Processing Speed (SDMT 
oral (t(18) = -2.156, p = .045)), Motor skills (Purdue pegboard non preferred hand (t(16) = -
2.28, p = .037), and Executive Function (DKEFS trail making number sequencing (t(16) = -
2.50, p = .023), such that patients diagnosed in the post puberty onset group performed 
superior than those diagnosed pre-puberty. See Table 11 for results.  
 
Table 11. Comparison  of measures of Processing Speed, Motor Skills, and Executive 
Function between groups divided by puberty onset at time of diagnosis.  
 
Neurocognitive Domain 
Measure 
Age: Puberty onset  
T 
 
df Pre-puberty (<10 years of 
age) 
Puberty onset (< 10 
years of age) 
Processing Speed     
SDMT oral -1.43 
(2.18) 
.21 
(1.03) 
-2.15* 18 
     
Motor Skill     
Purdue Pegboard non-
preferred hand 
-2.06 
(2.12) 
-.36 
(.93) 
-2.28* 16 
     
Executive Function     
DKEFS TMT number 
sequencing  
-.83 
(1.67) 
.60 
(.62) 
-2.50* 16 
     
     
Note. * = p ≤ .05, ** = p ≤ .005. Standard deviations appear in the parentheses below the 
means (reported as z-scores).  
 
  
 
Medication consumption at time of testing 
Comparisons for medication consumption at the time of testing (no consumption n = 8, 
consumption n = 10), revealed differences in the following domains: Intelligence, visual 
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memory, Motor skills, and Executive Function. Analyses revealed that that those who were 
not on medication performed superior than those on medication at the time of testing. The 
results are presented in Table 12 through Table 15. 
 
Table 12. Comparison of measures of Intelligence for medication consumption at the time of 
testing.  
 
Intelligence Quotients 
Medication consumption  
T 
 
df No consumption Consumption 
     
WASI Full Scale IQ .94 
(.65) 
-.21 
(1.40) 
2.17* 18 
     
WASI Verbal IQ .68 
(.71) 
-.58 
(1.28) 
2.54* 18 
     
Note. * = p ≤ .05, ** = p ≤ .005. Standard deviations appear in the parentheses below the 
means.  
 
Table 13. Comparison of measures of Memory for medication consumption at the time of 
testing.  
 
Memory variables 
Medication consumption  
T 
 
df No consumption Consumption 
     
RCFT immediate recall -.07 
(.85) 
-1.32 
(1.33) 
2.33* 18 
     
RCFT delayed recall .31 
(.68) 
-1.24 
(1.35) 
3.00* 18 
     
RCFT recognition .49 
(.92) 
-.68 
(1.34) 
2.13 18 
     
RAVLT delayed recall .24 
(1.33) 
-1.42 
(1.84) 
2.16 17 
     
     
Note. * = p ≤ .05, ** = p ≤ .005. Standard deviations appear in the parentheses below the 
means (reported as z-scores).  
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Table 14. Comparison of measures of Motor Skills between medication consumption at the 
time of testing.  
 
Motor Skill variables 
Medication consumption  
T 
 
df No consumption Consumption 
     
Purdue Pegboard non 
preferred hand 
-.12 
(1.35) 
-1.91 
(1.67) 
2.44* 16 
     
Purdue Pegboard both 
hands 
-.36 
(1.67) 
-2.20 
(1.83) 
2.19* 16 
     
Purdue Pegboard 
assemblies 
-1.22 
(.54) 
-3.06 
(1.95) 
2.56* 16 
     
     
Note. * = p ≤ .05, ** = p ≤ .005. Standard deviations appear in the parentheses below the 
means (reported as z-scores).  
 
 
Table 15. Comparison of measures of Executive Function between medication consumption at 
the time of testing.  
 
Executive Funciton 
variables 
Medication consumption  
T 
 
df No consumption Consumption 
     
DKEFS verbal fluency 
FAS 
1.19 
(1.38) 
-.60 
(1.45) 
2.60* 16 
     
DKEFS verbal fluency 
category 
2.33 
(.83) 
-.21 
(1.56) 
3.92** 16 
     
DKEFS verbal fluency 
switching accuracy 
1.09 
(.73) 
.02 
(.86) 
2.69* 16 
     
DKEFS TMT number 
sequencing 
.66 
(.61) 
.-59 
(1.58) 
2.12* 16 
     
DKEFS TMT motor 
speed 
.58 
(.23) 
-.48 
(1.04) 
2.82* 15 
     
WCST total errors .68 
(.59) 
-.38 
(.93) 
2.87* 18 
     
WCST preseverative 
errors 
.74 
(.45) 
-.14 
(.73) 
3.03* 18 
     
WCST non 
preseverative errors 
.47 
(.55) 
-.65 
(1.04) 
2.77* 18 
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WCST conceptual level 
responses 
.76 
(.96) 
-.46 
(.85) 
2.99* 18 
     
     
Note. * = p ≤ .05, ** = p ≤ .005. Standard deviations appear in the parentheses below the 
means (reported as z-scores).  
 
 
Time elapsed since diagnosis 
Time elapsed since diagnosis was analyzed by splitting the group by 5 to 15 years since 
diagnosis (n = 11) and greater than 15 years since diagnosis (n = 9). Comparisons revealed 
differences in Executive Function alone whereby patients in the less than 15 years group 
performed superior than the group with more time elapsed. The results are presented in Table 
16.  
 
Table 16. Comparison of measures of Executive function between the number of years 
elapsed between testing and tumour diagnosis.  
 
Executive Function 
variables 
Elapsed time  
T 
 
df 5-15 years 15+ years 
     
WCST total errors .43 
(.52) 
-.43 
(1.18) 
2.19* 18 
     
WCST perseverative 
responses 
.53 
(.60) 
-.27 
(.78) 
2.58* 18 
     
WCST perseverative 
errors 
.55 
(.57) 
-.20 
(.79) 
2.48* 18 
     
WCST non 
preseverative errors 
.23 
(.63) 
-.74 
(1.19) 
2.34* 18 
     
Note. * = p ≤ .05, ** = p ≤ .005. Standard deviations appear in the parentheses below the 
means (reported as z-scores).  
 
 
 
Inquiry 4. Explore differences in neuropsychological scores based on tumour 
related factors.  
 
Independent t-tests. 
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A series of independent t-tests was conducted across all dependent measures of 
neurocognitive functioning for the following tumour related parameters: tumour location, 
tumour pathology, treatment methods, and symptoms at time of diagnosis.  Analyses were not 
conducted by level of dysfunction since too few patients were included in each subgroup. See 
Appendix D for tumour related factors by level of dysfunction.   
 
Tumour location 
Comparisons between patients with infratentorial (n = 11) and supratentorial (n = 9) tumours 
demonstrated no significant differences on all neuropsychological variables. 
 
Tumour pathology 
The impact of tumour pathology on cognitive function was analysed by type of glioma, 
astrocytoma (n = 17) versus other gliomas (n = 3). Comparisons between these groups of 
patients revealed significant differences in Executive Function (DKEFS verbal fluency 
category total (t(16) = 2.52, p = .023; and DKEFS trail making motor speed (t(15) = 2.75 , p = 
.015)), with the astrocytoma pathology group showing better performance. See Table 17 for 
results.  
 
Table 17. Comparison of measures of Executive function by tumour pathology.   
 
Executive Function 
variables 
Tumour Pathology  
T 
 
df Astrocytoma Other glioma 
     
DKEFS verbal fluency 
category total 
1.20 
(1.59) 
-1.33 
(1.52) 
2.52* 16 
     
DKEFS TMT motor 
speed 
.26 
(.60) 
-1.13 
(1.50) 
2.75* 15 
     
     
Note. * = p ≤ .05, ** = p ≤ .005. Standard deviations appear in the parentheses below the 
means (reported as z-scores).  
 
40 
 
Treatment methods 
Comparisons between patients who underwent surgery alone (n = 17) and those with radiation 
or chemotherapy in addition to surgery (n = 3) also showed no significant differences across 
the neuropsychological test variables. 
Symptoms at time of diagnosis 
Comparisons between patients who experienced symptoms of hydrocephalus or seizures (n = 
15) at the time of diagnoses and those who did not (n = 5) revealed no significant differences 
across the neuropsychological measures. 
 
Part B: Perceived Health and Cognitive Quality of Life 
 
Inquiry 1. Identify domains of strengths and weaknesses in the sample 
population’s perceived health and cognitive quality of life.   
 
The sample population completed a health related quality of life questionnaire (RAND-36) 
and a perceived cognitive functioning questionnaire (FACT-Cognitive Function version 3). 
As indicated in the Methods section: Table 4, the RAND-36 has eight scales measuring the 
following health related domains: Physical functioning, Role limitations due to physical 
health, role limitations due to emotional problems, Energy/fatigue, Emotional well-being, 
Social functioning, Pain, and General health. Subscales measured in the FACT-Cog include: 
Perceived Cognitive Impairment (measures participant’s perception of their attention, 
memory, spatial awareness, and processing speed), Comments from others (measures 
participant’s perception of how others rate their ability to remember information, think and 
speak clearly, and appear confused), Perceived cognitive abilities (measures participant’s 
perception of their ability to concentrate, shift between tasks, and remember items), and 
Impact on quality of life (measures participant’s perception of how their cognitive problems 
interfere with their emotions, work, and general life enjoyment). Both scales were recoded 
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such that greater scores indicate superior performance (ie. less impairment). To note, the 
RAND-36 scores are presented as z-scores and the FACT-Cog scores are raw scores.  
Normed referenced data does not exist for the FACT-Cog, although studies have documented 
excellent test-retest reliability, convergent validity with the EORTC-30 Cognitive Functioning 
Scale, and evidence of discriminant validity (Jacobs et al., 2007). 
  
Table of frequencies.  
The scores on the RAND-36 and the FACT-Cog are presented as percentage frequency tables. 
Tables X and Y illustrate how the participants rated their perceived quality of life, with some 
subscales rated more frequently in the positive direction than others. For example, the 
percentage frequency of the participants that rated scores on the “RAND-36: Role limitations 
due to physical health” above 1 standard deviation was 61.11%, suggesting that the majority 
of the sample did not endorse physical health as a role limitation. In addition, the majority of 
the sample (%f = 52.94) positively rated their “General health” on the questionnaire, whereas 
a proportion of the sample endorsed challenges with on the General Health subscale (%f = 
29.41).  
 
The percentage frequency table for the FACT-Cog questionnaire indicates the number of 
individuals who rated their abilities in the top and bottom quartiles on each subscale. The 
results indicate that a large proportion of the sample perceived few challenges on the impact 
of their cognitive function on quality of life (%f = 76.47). 
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Table 18. Percentage of participants who rated each RAND-36 subscale above and below 1 
standard deviation (SD). 
 
 
RAND-36 Subscale 
 
N 
 
% of sample <1 SD 
 
% of sample >1SD 
Physical functioning 
 
18 11.11 44.44 
Role limitations due to physical health 
 
18 11.11 61.11 
Role limitations due to emotional problems 
 
18 11.11 0 
Energy/Fatigue 
 
17 11.76 35.29 
Emotional well-being 
 
17 11.76 11.76 
Social functioning 
 
17 11.76 0 
Pain 
 
17 
 
11.76 
 
29.41 
 
General Health 
 
17 29.41 52.94 
    
 
 
Table 19.Percentage of participants who rated each of the FACT-Cog subscales in the top and 
bottom quartiles. 
 
 
FACT-Cog Subscale 
 
N 
 
% of sample rated 
scores in bottom 
quartile  
 
% of sample in top 
quartile 
Perceived cognitive impairment (/72) 
 
17 5.88 41.17 
Comments from others (/16) 
 
17 5.88 62.50 
Perceived cognitive abilities (/28) 
 
17 0 41.17 
Impact on quality of life (/16) 
 
17 11.76 76.47 
    
Note: Perceived cognitive impairment: bottom quartile = 18/72, top quartile = 54/72; 
Comments from others: bottom quartile = 4/16, top quartile = 12/16; Perceived cognitive 
abilities: bottom quartile = 7/28, top quartile = 21/28, Impact on quality of life: bottom 
quartile = 4/16, top quartile = 12/16. 
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Analysis of Variance: One-way Repeated Measures.  
A series of analyses of variance was conducted with the eight measures of health related 
quality of life from the RAND-36 in order to determine if differences existed between the 
subscales in the sample. The analyses were not performed on the FACT-Cog subscales due to 
unequal number of items per scale (i.e., one scale can not be compared to the other due to 
different denominators). 
 
Perceived health realted quality of life questionnaire: RAND-36. 
Mauchly’s test of sphericity indicated that the assumption of sphericity was assumed χ2(27) = 
39.714, p = .06. The results demonstrated that there was a main effect of scale, F(7, 112) = 
3.06, p = .005. Post-hoc analyses revealed that the “Physical functioning” scale (M = .50, SD 
= .84) was significantly different from the “Social functioning” scale (M = -.15, SD = 1.14), 
and the “Role limitations due to physical health” scale (M = .65, SD = .82) was significantly 
different than the “Social functioning” scale (M = -.15, SD = 1.14. Both comparisons 
indicated that the sample perceived their physical health more favourably than their social 
functioning. Figure 3 displays the means for each subscale. Table 20 presents the results of 
the repeated measures analysis.   
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Figure 3. Graph of mean z-score for each of the subscales on the RAND-36 (with confidence intervals).  
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Table 20. Repeated measures analysis of variance on subscales of the RAND-36 
  
 
Effect 
  
P MS df F 
 
RAND-36 subscales 
 
1.23 
 
7 
 
3.06 
 
.005** 
     
     
 
 
 
Inquiry 2. Explore the inter-group variation in the quality of life questionnaires.  
 
 Analysis of Variance. 
A series of analyses of variance was conducted across all subscales from the RAND-36 and 
FACT-cog across the three neurocognitive groups outlined in Chapter 1 (“Severe 
Dysfunction”, “Moderate Dysfunction”, and “Mild Dysfunction”).  Descriptive statistics for 
each perceived health related and cognitive quality of life measure by level of dysfunction are 
presented in Appendix E and F, respectively.  The Bonferroni correction was used to identify 
significant effects (i.e., p =.05/7).  In addition, since the analyses are exploratory only results 
at the significant level will be reported.  
 
 Post-Hoc Contrast Analyses.  
In order to determine the group differences between the levels of dysfunction, a series of post-
hoc contrast analyses was conducted (Severe dysfunction vs. Moderate dysfunction; Severe 
dysfunction vs. Mild dysfunction; and Moderate dysfunction vs. Mild dysfunction). Post hoc 
comparisons using the Tukey HSD were obtained for measures of equal variances assumed 
and the Dunnett T3 for the measures where equal variances were not assumed.  
  
Analyses of variance revealed significant differences between groups in the following 
subscales of the RAND-36: Physical Function, Social Function and in the FACT-Cog: 
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Comments from Others. Figure 4 illustrates the mean z-scores of each subscale by level of 
dysfunction.   
 
 
Figure 4. Mean scores of the RAND-36 subscales by level of dysfunction. 
 
Note: Scales are numbered 1 through 8 representing the following labels: 1-Physical 
functioning, 2-Role limitations due to physical health, 3-role limitations due to emotional 
problems, 4-Energy/fatigue, 5- Emotional well-being, 6-Social functioning, 7-Pain, and 8-
General health. Marginal means are presented as z-scores.  
 
 
Perceived health related quality of life: RAND-36. 
Analyses of variances revealed a significant main effect of group on the Physical function 
subscale (F(2,15) = 10.38, p = .001), Social Function (F(2,14) = 10.73, p = .006), and 
Emotional well-being approached significance (F(2,14) = 6.65 = .009). 
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Post-hoc comparisons across the first two health related subscales revealed that the mean z-
score for the Severe Dysfunction group was significantly lower than the Moderate and Mild 
Dysfunction groups. No differences between the Moderate and Mild groups were found.  The 
results are presented in Table 21.  
 
Table 21. Analysis of variance on subscales of the RAND-36 by level of dysfunction 
 
 
RAND-36 
Level of Dysfunction  
F 
 
η2 Severe Moderate Mild 
 
Physical Function 
 
-.62a 
 
.84b 
 
.89b 
 
10.38** 
 
.58 
 (1.05) (.20) (.48)   
 
Social Function 
 
-1.50a 
 
-.07b 
 
.55 b 
 
7.58* 
 
.52 
 (.93) (1.09) (.48)   
 
Emotional Function 
 
-1.34a 
 
.14a 
 
.62 a 
 
6.65* 
 
.48 
 (1.33) (.77) (.60)   
      
Note. * = p ≤ .01 ** = p ≤ .001. Standard deviations appear in the parentheses below the 
means (reported as z-scores). Means with differing subscripts within rows are significantly 
different at the p ≤ .05 based on Tukey’s HSD (homogeneity of variance assumed) and 
Dunnett T3(homogeneity of variance not assumed).  
 
 
Perceived cognitive quality of life: FACT-Cog. 
 
Analyses of variance revealed a significant main effect of group on the Comments from 
Others subscale (i.e., participant’s perception of how others rate their ability to remember 
information, think and speak clearly, and appear confused) (F(2,14) = 12.74, p = .001), 
although post-hoc comparisons (Dunnett T3; homogeneity of variance not assumed) 
demonstrated marginally significant differences between the Severe Dysfunction group (M = 
7.75, SD = 4.27) and the Mild Dysfunction group (M = 15.43, SD = .54), p = .08. Figure 5. 
displays the mean raw score for each subscale by level of dysfunction.  
 
 
 
 
 
48 
 
 
 
Figure 5. Mean scores of the FACT-Cog subscales by level of dysfunction 
 
Note: Scales are numbered 1 through 4 representing the following labels: 1-Perceived 
cognitive impairment, 2-Comments from others, 3-Perceived cognitive abilities, 4-Impact on 
quality of life.  Marginal means are presented as raw scores. Greater scores suggest less 
impairment.  
 
 
Inquiry 3. Explore differences in perceived quality of life scores based on 
demographic variables.  
 
 Independent t-tests. 
A series of independent t-tests was conducted across the quality of life subscales by sex, 
education, age at diagnosis, medication consumption at time of testing, and time elapsed 
between testing and diagnosis. Analyses were not conducted by level of dysfunction since too 
few patients were included in each subgroup. See Appendix G and H for demographic data by 
level of dysfunction.   
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Sex 
Comparisons between men (n = 10) and women (n = 7) demonstrated that women (M = -.71, 
SD = 1.25) had significantly lower scores than men (M = .47, SD = .77) on the RAND-36: 
Emotional well-being subscale (t(15) = -2.424, p = .028). No significant differences were 
found across the other RAND-36 and FACT-Cog subscales.  
 
Education 
Education (divided by Post High School education, n = 11 versus High School diploma/No 
High School diploma, n = 7) demonstrated significant differences on 11 of the 12 subscales at 
a significance level of p < 0.05, whereby individuals with Post High School education rated 
their quality of life more favourably than those with either no High School diploma or with a 
High School diploma alone. See Table 22 for results for the independent samples analyses.  
 
Table 22. Comparison between levels of education on perceived quality of life measures 
(QoL). 
 
QoL 
Education  
T 
 
df No High School Diploma/ 
High School Diploma 
 
Post High School 
education 
RAND-36     
   Physical functioning .03 
(1.11) 
.86 
(.38) 
-2.31* 16 
     
   Role limitations due to 
physical health 
.19 
(1.05) 
.98 
(.39) 
-2.30* 16 
     
   Role limitations due to 
emotional problems 
-.21 
(1.13) 
.62 
(.53) 
-2.12* 16 
     
   Energy/fatigue -.51 
(.86) 
.53 
(.84) 
-2.41* 15 
     
   Emotional well-being -.87 
(1.39) 
.46 
(.63) 
-2.74* 15 
     
   Social functioning -1.38 
(.97) 
.52 
(.45) 
-5.57** 15 
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   Pain -.36 
(.98) 
.73 
(.51) 
-3.05** 15 
     
   General Health -.25 
(1.42) 
.85 
(1.22) 
-1.68 15 
     
FACT-Cog     
   Perceived cognitive 
impairment 
37.17 
(15.97) 
55.27 
(10.47) 
-2.83* 15 
     
   Comments from 
others 
10.50 
(5.39) 
14.55 
(1.86) 
-2.30* 15 
     
   Perceived cognitive 
abilities 
15.67 
(5.13) 
21.09 
(4.35) 
-2.31* 15 
     
   Impact on QoL 
 
8.67 
(5.72) 
14.73 
(1.42) 
-3.41** 15 
Note. * = p ≤ .05, ** = p ≤ .001. Standard deviations appear in the parentheses below the 
means. Means reported as z-scores for the RAND-36 subscales, and as raw scores for the 
FACT-Cog subscales.  
 
 
Age at diagnosis 
Age at diagnosis was defined categorically along two dimensions: chronological age 6-11 (n 
= 12 ) versus 12-18 (n = 8) and puberty onset (<10 years of age n = 10 and >10 years of age n 
= 10). Comparisons for age at diagnosis by chronological age and by puberty onset revealed 
no significant differences across the perceived quality of life measures. 
 
Medication consumption at time of testing 
Comparisons between medication consumption at the time of testing (no consumption n = 8, 
consumption n = 9) by quality of life revealed differences in the following six subscales: 
RAND-36 Physical functioning, Energy/fatigue, Emotional well-being, Social Functioning, 
General health, and FACT-Cog Impact on quality of life. Analyses revealed that those who 
were not on medication rated their health and cognitive abilities significantly more favourably 
than those on medication at the time of testing. The results are presented in Table 23. 
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Table 23. Comparison of perceived quality of life measures (QoL) by medication 
consumption. 
 
QoL 
Medication Consumption  
T 
 
df No Consumption Consumption 
RAND-36     
   Physical functioning 1.00 
(.13) 
.16 
(.97) 
2.43* 16 
     
   Role limitations due to 
physical health 
.10 
(.28) 
.42 
(.99) 
1.60 16 
     
   Role limitations due to 
emotional problems 
.64 
(.38) 
 
.02 
(1.09) 
1.51 16 
     
   Energy/fatigue .71 
(.58) 
-.32 
(1.00) 
2.55* 15 
     
   Emotional well-being .64 
(.58) 
-.60 
(1.21) 
2.64* 15 
     
   Social functioning .52 
(.45) 
-.75 
(1.24) 
2.73* 15 
     
   Pain .57 
(.77) 
.14 
(.94) 
1.02 15 
     
   General Health 1.44 
(.87) 
-.41 
(1.11) 
3.79* 15 
     
FACT-Cog     
   Perceived cognitive 
impairement 
53.50 
(11.31) 
44.78 
(17.41) 
1.21 15 
     
   Comments from 
others 
13.88 
(2.42) 
12.44 
(4.92) 
.74 15 
     
   Perceived cognitive 
abilities 
20.25 
(4.74) 
18.22 
(5.70) 
.79 15 
     
   Impact on QoL 
 
15.00 
(1.20) 
10.44 
(5.34) 
2.35* 15 
Note. * = p ≤ .05, ** = p ≤ .001. Standard deviations appear in the parentheses below the 
means. Means reported as z-scores for the RAND-36 subscales, and as raw scores for the 
FACT-Cog subscales. 
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Time elapsed between testing and diagnoses 
Time elapsed since diagnosis was analyzed by splitting the group by those diagnosed 5 to 15 
years from date of testing (n = 10) and greater than 15 years since diagnosis (n = 7). No 
significant differences were found between groups on measures of perceived quality of life.  
 
Inquiry 4. Explore differences in perceived quality of life scores based on tumour 
related factors.  
 
 Independent t-tests. 
A series of independent t-tests was conducted across the quality of life subscales by the 
following tumour related parameters: tumour location, tumour pathology, treatment methods, 
and symptoms at diagnosis. Analyses were not conducted by level of dysfunction since too 
few patients were included in each subgroup. See Appendix I and J for tumour related data by 
level of dysfunction.   
 
Tumour location 
Comparisons between patients with infratentorial (n = 9) and supratentorial (n = 9) tumours 
demonstrated no significant differences on any perceived quality of life subscales.  
 
Tumour pathology 
Tumour pathology was analysed by type of glioma, astrocytoma (n = 15) versus other gliomas 
(n = 2) across all the perceived quality of life subscales. Comparisons between these patients 
revealed no significant differences (p < 0.05).  
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Treatment methods 
Comparisons between patients who underwent surgery alone (n = 14) and those with radiation 
or chemotherapy in addition to surgery (n = 3) also showed non-significant differences (p < 
0.05) across the perceived quality of life subscales.  
 
Symptoms at diagnoses  
Lastly, comparisons between patients who experienced symptoms of hydrocephalus or 
seizures (n = 11) at the time of diagnoses and those who did not (n = 6) revealed no 
significant differences across the perceived quality of life subscales. 
 
Inquiry 5. Explore relationships between perceived health and cognitive related 
quality of life scores.  
 
 Correlations. 
Pearson product-moment correlations were computed between the RAND-36 subscales and 
the FACT-cog subscales. Positive correlations between perceived health and cognitive 
function subscales indicated that the more participants rated their health quality of life as 
enhanced, the better they perceived their cognitive function. The results are presented in Table 
24.  
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Table 24. Correlation matrix between the FACT-Cog and RAND-36 subscales.  
Note: * = p ≤ .05 (2-tailed), ** = p ≤ .01 (2-tailed) 
  
RAND-36: 
physical 
functioning z 
score 
RAND-36: 
role 
limitations 
due to 
physical 
health 
RAND-36: 
role 
limitations 
due to 
emotional 
problems 
RAND-36: 
energy/fatigue 
RAND-36: 
emotional 
well-being 
RAND-36: 
social 
functioning 
RAND-
36: pain 
RAND-
36: 
general 
health 
 
FACT-cog: 
perceived 
cognitive 
impairment 
raw score 
(/72)  
 
Pearson 
Correlation 
 
.674
**
 
 
.218 
 
.550
*
 
 
.567
*
 
. 
746
**
 
 
.722
**
 
. 
358 
 
.513
*
 
Sig. (2-tailed) .00 .400 .022 .018 .001 .001 .158 .035 
N 
17 17 17 17 17 17 17 17 
 
FACT-cog: 
comments 
from others 
raw score 
(/16) 
 
Pearson 
Correlation 
.681
**
 .008 .397 .312 .661
**
 .566
*
 -.011 .298 
Sig. (2-tailed) .003 .977 .114 .223 .004 .018 .966 .245 
N 
17 17 17 17 17 17 17 17 
 
FACT-cog: 
perceived 
cognitive 
abilities raw 
score (/28) 
 
Pearson 
Correlation 
 
.529
*
 
 
.346 
 
.588
*
 
 
.715
**
 
 
.727
**
 
 
.621
**
 
 
.468 
 
.668
**
 
Sig. (2-tailed) .029 .174 .013 .001 .001 .008 .058 .003 
N 
17 17 17 17 17 17 17 17 
 
FACT-cog: 
impact on 
quality of life 
raw score 
(/16) 
 
 
Pearson 
Correlation  
 
.822
**
 
 
.449 
 
.690
**
 
 
.716
**
 
 
.907
**
 
 
.872
**
 
 
.474 
 
.774
**
 
Sig. (2-tailed) .000 .071 .002 .001 .000 .000 .055 .000 
N 
17 17 17 17 17 17 17 17 
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Inquiry 6. Explore relationships between perceived cognitive related quality of 
life scores and IQ.  
 
Correlations. 
Pearson product-moment correlations were computed between the RAND-36 subscales, the 
FACT-cog subscales, and measures of Intelligence (WASI-Verbal IQ, WASI-Performance 
IQ, and WASI-Full Scale IQ), independently. 
 
Positive correlations between measures of intelligence with both perceived health and 
cognitive subscales indicated that increased performance in cognitive function was in line 
with increased perceptions of adequate quality of life.  The results are presented in Table 25 
and 26.  
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Table 25. Correlation Matrix between measures of Intelligence and the RAND-36 subscales.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                    
 
 
 
 
 
Note: * = p ≤ .05 (2-tailed), ** = p ≤ .01 (2-tailed). 
 
 
 
 
 
 
 
 
 
  
RAND-36: 
physical 
functioning 
z score 
RAND-
36: role 
limitations 
due to 
physical 
health 
RAND-
36: role 
limitations 
due to 
emotional 
problems 
RAND-36: 
energy/fatigue 
RAND-
36: 
emotional 
well-
being 
RAND-36: 
social 
functioning 
RAND-
36: pain 
RAND-
36: 
general 
health 
WASI: verbal 
IQ z score 
Pearson 
Correlation 
.833
**
 .430 .457 .681
**
 .821
**
 .802
**
 .338 .716
**
 
Sig. (2-tailed) .000 .075 .056 .003 .000 .000 .184 .001 
N 18 18 18 17 17 17 17 17 
 
WASI: 
performance 
IQ z score 
Pearson 
Correlation 
.735
**
 .199 .217 .456 .607
**
 .605
*
 .129 .494
*
 
Sig. (2-tailed) .001 .429 .386 .066 .010 .010 .621 .044 
N 18 18 18 17 17 17 17 17 
 
WASI: full 
scale IQ z 
score 
Pearson 
Correlation 
.814
**
 .361 .369 .598
*
 .742
**
 .755
**
 .271 .607
**
 
Sig. (2-tailed) .000 .141 .132 .011 .001 .000 .292 .010 
N 18 18 18 17 17 17 17 17 
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Table 26. Correlation Matrix between measures of Intelligence and the FACT-cog subscales.  
 
 
 
FACT-cog: 
perceived cognitive 
impairment raw 
score (/72) 
FACT-cog: 
comments from 
others raw score( 
/16) 
FACT-cog: 
perceived 
cognitive 
abilities raw 
score (/28) 
FACT-cog: impact 
on quality of life 
WASI: verbal IQ z score Pearson Correlation .776
**
 .745
**
 .648
**
 .785
**
 
Sig. (2-tailed) .000 .001 .005 .000 
N 17 17 17 17 
WASI: performance IQ      
z score 
Pearson Correlation .641
**
 .747
**
 .475 .576
*
 
Sig. (2-tailed) .006 .001 .054 .015 
N 17 17 17 17 
WASI: full scale IQ z score Pearson Correlation .751
**
 .781
**
 .586
*
 .714
**
 
Sig. (2-tailed) .001 .000 .014 .001 
N 17 17 17 17 
 
Note: * = p ≤ .05 (2-tailed), ** = p ≤ .01 (2-tailed). 
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Part C: Measures of Adaptive Functioning 
 
Inquiry 1. Identify domains of strengths and weaknesses in the sample population’s 
adaptive functioning. 
The sample population completed an adaptive functioning questionnaire (Adult Self-Report: 
ASR). As indicated in the Methods section: Table 4, the ASR has five self-perception scales 
measuring the following adaptive functioning domains: Mean adaptive (reflects perceptions of 
effectiveness and satisfaction with friends, family, and job/education), Personal Strengths 
(identifies perceptions of their attitude and code of conduct such as honesty, fairness, and ability 
to meet responsibilities), Internalizing symptoms (identifies behaviours related to anxiety and 
depression) , Externalizing symptoms (identifies behaviours related to aggression, rule-breaking 
and intrusion), and Total Problems (score reflects an aggregate of the Externalizing and 
Internalizing symptoms). T-scores have been calculated such that the first two domains are 
interpreted as T-scores greater than 35 are within the normal range and the latter three domains 
are interpreted as T-scores less than 60 are within the normal range.  
 
 Table of frequencies.  
The counts of the sample scores on the ASR are presented as percentage frequency. Table 27 
illustrates the range of scores in the normal range reported across the subscales. More than half 
of the sample rated their adaptive function in the normal range across the subscales (%f = 55.56 – 
83.33, Internalizing symptoms and Personal Strengths, respectively).   
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Table 27. Percentage of sample who rated each ASR subscale within the normative range 
utilizing norm standardized T-score cut off points.  
 
 
ASR subscales 
 
N 
 
% of sample within normal range 
Mean Adaptive Score 18 77.78 
Personal Strengths 18 83.33 
Internalizing symptoms 18 55.56 
Externalizing symptoms 18 66.67 
Total Problems 18 66.67 
 
 
Analysis of Variance: One-way Repeated Measures  
 
A series of analyses of variance was conducted with the five measures of adaptive functioning 
from the ASR in order to determine if differences existed between the subscales in the sample.  
Mauchly’s test indicated that the assumption of sphericity was violated, χ2(9) = 74.31, p = .00, 
therefore degrees of freedom were corrected using Greenhouse-Geisser estimates of sphericity (ɛ 
= .32). The results demonstrated that there was no significant differences between ratings on 
each of the adaptive functioning subscales, F(1.30, 22.01) = 1.62, p = .22. Figure 6 displays the 
means for each subscale.  
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.  
Figure 6. Graph of mean T-score for each of the subscales on the Adult Self-Report Measure 
with confidence intervals. 
 
Inquiry 2. Explore the inter-group variation across the adaptive measures.  
  
Analysis of Variance. 
A series of analyses of variance was conducted across all subscales from the ASR between the 
three neurocognitive groups outlined in Chapter 1 (“Severe Dysfunction”, “Moderate 
Dysfunction”, and “Mild Dysfunction”).  Descriptive statistics for each adaptive measure by 
level of dysfunction are presented in Appendix K.  The Bonferroni correction was used to 
identify significant effects (i.e., p =.05/2). In addition, since the analyses are exploratory only 
results at the significant level are reported. 
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 Post-Hoc Contrast Analyses.  
In order to determine the group differences between the levels of dysfunction, a series of post-
hoc contrast analyses were conducted (Severe dysfunction vs. Moderate dysfunction; Severe 
dysfunction vs. Mild dysfunction; and Moderate dysfunction vs. Mild dysfunction). Post hoc 
comparisons using the Tukey HSD were obtained for measures of equal variances assumed and 
the Dunnett T3 for the measures where equal variances were not assumed.  
 
Analyses of variances revealed marginal main effects of group on the Externalizing symptoms 
subscale (F(2,15) = 3.58, p = .05) and the Total problems subscale (F(2,15) = 4.19, p = .04). 
Post-hoc comparisons between the groups on the Externalizing and Total problems subscales 
revealed that the mean T-score for the Severe Dysfunction group was significantly higher than 
the Mild Dysfunction group, suggesting that the Severe Dysfunction group endorsed more 
challenges than the Mild Dysfunction group. No differences were found between the Moderate 
and Severe group and the Moderate and Mild groups.  The results are presented in Table 28 and  
Figure 7 illustrates the mean T-scores of each subscale by level of dysfunction. 
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Table 28. Analyses of variance on subscales of the Adult Self-Report questionnaire (ASR) by 
level of dysfunction 
 
 
ASR 
Level of Dysfunction  
F 
 
η2 Severe Moderate Mild 
 
Mean Adaptive  
 
41.25 a 
 
48.29 a 
 
53.71 a 
 
1.69 
 
.18 
 (11.09) (13.60) (6.92)   
 
Personal strengths 
 
50.25 a 
 
50.29 a 
 
48.71 a  
 
.05 
 
.01 
 (5.12) (12.63) (10.69)   
 
Internalizing symptoms 
 
66.50 a 
 
58.57 a 
 
47.71 a 
 
2.58 
 
.26 
 (14.48) (13.05) (13.89)   
 
Externalizing symptoms 
 
64.75 a 
 
54.86 ac 
 
49.00  bc 
 
3.58* 
 
.32 
 (4.72) (10.50) (9.97)   
 
Total Problems 
 
66.50 a 
 
56.14 ac 
 
48.71 bc 
 
4.19* 
 
.36 
 (9.26) (9.67) (10.26)   
Note. * = p ≤ .05 ** = p ≤ .01.  Standard deviations appear in the parentheses below the means. 
Means are presented as T-scores whereby the Mean Adaptive and Personal Strengths scales are 
interpreted as T-scores > 35 are within the normal range and in the Internalizing, Externalizing, 
and Total Problems scales T-scores < 60 are within the normal range. Means with differing 
subscripts within rows are significantly different at the p ≤ .05 based on Tukey’s HSD 
(homogeneity of variance assumed) and Dunnett T3 (homogeneity of variance not assumed).  
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Figure 7. Mean T-scores on each subscale of the Adult Self-Report Measure (ASR) by level of 
dysfunction. 
 
Inquiry 3. Explore differences in perceived quality of life scores based on 
demographic variables.  
 Independent t-tests. 
A series of independent t-tests was conducted across the adaptive measures subscales by sex, 
education, age at diagnosis, medication consumption at time of testing, and time elapsed between 
testing and diagnosis. Analyses were not conducted by level of dysfunction since too few 
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patients were included in each subgroup. See Appendix L for demographic data by level of 
dysfunction.   
 
Sex 
Comparisons between men (n = 10) and women (n = 8) demonstrated that men had significantly 
lower scores than women on the ASR-Internalizing (t(16) = 2.68, p = .016) and the ASR-Total 
Problems scale (t(16) = 2.28, p = .037). No significant differences were found across the other 
three measures (at p < 0.05) of adaptive functioning. See table 29 for results from the 
independent sample t-tests. 
 
 
Table 29.Comparison of sex on self-report measures of adaptive functioning from the Adult Self-
Report questionnaire (ASR). 
 
ASR subscales 
Sex  
t 
 
df Women Men 
 
     
   Mean adaptive 45.50 
(12.34) 
51.50 
(10.21) 
-1.13 16 
     
   Personal Strengths 48.13 
(11.92) 
50.90 
(8.83) 
-.59 16 
     
   Internalizing 65.13 
(11.28) 
48.90 
(13.80) 
2.68* 16 
     
   Externalizing 59.50 
(7.67) 
51.00 
(11.65) 
1.77 16 
     
   Total Problems 61.75 
(8.83) 
50.60 
(11.36) 
 
2.28* 16 
Note. * = p ≤ .05, ** = p ≤ .001. Standard deviations appear in the parentheses below the means. 
Means are presented as T-scores whereby the Mean Adaptive and Personal Strengths scales are 
interpreted as T-scores > 35 are within the normal range and in the Internalizing, Externalizing, 
and Total Problems scales T-scores < 60 are within the normal range.  
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Education 
There were significant between education group differences (divided by versus High School 
diploma/No High School diploma, n = 7 versus Post High School education, n = 11) on three 
subscales at a significance level of p < 0.05, whereby individuals with a high school diploma or 
less education reported greater internalizing, externalizing, and overall total problems than those 
individuals with post high school education. In addition, the T-scores were in the borderline 
clinical range for the High School diploma/No High School diploma group across the 
aforementioned subscales.  See Table 30 for results from the independent sample t-tests. 
 
Table 30.Comparison of levels of education on self-report measures of adaptive functioning from 
the Adult Self-Report questionnaire (ASR). 
 
ASR subscales 
Education  
T 
 
Df No High School Diploma/ 
High School Diploma 
 
Post High School 
education  
 
     
   Mean adaptive 44.29 
(11.97) 
51.73 
(10.34) 
-1.40 16 
     
   Personal Strengths 49.14 
(7.90) 
50.00 
(11.64) 
-.17 16 
     
   Internalizing 65.43 
(13.62) 
50.18 
(12.91) 
2.39* 16 
     
   Externalizing 65.00 
(5.16) 
48.27 
(7.73) 
5.03** 16 
     
   Total Problems 65.57 
(8.12) 
49.18 
(8.45) 
 
4.07** 16 
Note. * = p ≤ .05, ** = p ≤ .001. Standard deviations appear in the parentheses below the means. 
Means are presented as T-scores whereby the Mean Adaptive and Personal Strengths scales are 
interpreted as T-scores > 35 are within the normal range and in the Internalizing, Externalizing, 
and Total Problems scales T-scores < 60 are within the normal range.  
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Age at diagnosis 
Age at diagnosis was defined categorically in two dimensions, by development age 6-11.12 (n = 
12 ) versus 12-18 (n = 8) and by puberty onset (<10 years of age n = 10 and >10 years of age n = 
10). Comparisons for age at diagnosis by development and by puberty onset revealed no 
significant differences across adaptive functioning scales. 
 
Medication consumption at time of testing 
Comparisons between medication consumption at the time of testing (no consumption n = 8, 
consumption n = 10) by measures of adaptive psychological function, revealed differences in all 
scales except the Externalizing scale.  Analyses revealed that that those who were not on 
medication rated their adaptive functioning significantly more favourably than those on 
medication at the time of testing. The mean T-scores in the Mean Adaptive and Personal 
Strengths scales indicate scores within the normal range for both groups. Whereas, the group 
taking medication at the time of testing had scores in the borderline range in the Internalizing and 
Total Problems scales. See Table 31 for results from the independent samples t-test for 
medication consumption.  
 
Table 31. Comparison of medication consumption on self-report measures of adaptive 
functioning from the Adult Self-Report questionnaire (ASR). 
 
ASR subscales 
Medication Consumption  
t 
 
df No Consumption 
 
Consumption 
 
     
   Mean Adaptive 55.88 
(1.78) 
43.20 
(12.60) 
2.81** 16 
     
   Personal Strengths 55.13 
(5.64) 
45.30 
(10.96) 
2.30* 16 
     
   Internalizing 45.50 64.60 -3.47** 16 
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(8.18) (13.69) 
     
   Externalizing 51.75 
(7.92) 
57.20 
(12.40) 
-1.08 16 
     
   Total Problems 49.00 
(8.52) 
60.80 
(11.21) 
 
-2.46* 16 
Note. * = p ≤ .05, ** = p ≤ .005. Standard deviations appear in the parentheses below the means. 
Means are presented as T-scores whereby the Mean Adaptive and Personal Strengths scales are 
interpreted as T-scores > 35 are within the normal range and in the Internalizing, Externalizing, 
and Total Problems scales T-scores < 60 are within the normal range.  
 
Time elapsed between testing and diagnoses 
Time elapsed since diagnosis was analyzed by splitting the group by those diagnosed 5 to 15 
years from date of testing (n = 11) and greater than 15 years since diagnosis (n = 7). No 
significant differences were found between groups on measures of adaptive psychological 
functioning.   
  
Inquiry 4. Explore differences in psychological adaptive functioning based on 
tumour related factors.  
  
Independent t-tests. 
A series of independent t-tests were conducted across the adaptive functioning subscales by the 
following tumour related parameters: tumour location, tumour pathology, treatment methods, 
and symptoms at diagnosis. Analyses were not conducted by level of dysfunction since too few 
patients were included in each subgroup. See Appendix M for tumour related data by level of 
dysfunction.  Significant differences were determined based on a 2-tailed alpha of < 0.05. 
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Tumour location 
Comparisons between patients with infratentorial (n = 9) and supratentorial (n = 9) tumours 
demonstrated no significant differences on any perceived quality of life subscales.  
 
Tumour pathology 
Tumour pathology was analysed by type of glioma, astrocytoma (n = 16) versus other gliomas (n 
= 2) across all the adaptive functioning subscales. Comparisons between these groups revealed 
no significant differences.  
 
Treatment methods 
Comparisons between patients who underwent surgery alone (n = 15) and those with radiation or 
chemotherapy in addition to surgery (n = 3) also showed non-significant differences across the 
adaptive functioning subscales.  
 
Symptoms at diagnoses  
Lastly, comparisons between patients who experienced symptoms of hydrocephalus or seizures 
(n = 11) at the time of diagnoses and those who did not (n = 7) revealed no significant 
differences across the adaptive functioning subscales.  
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Inquiry 5. Explore relationships between adaptive functioning and perceived health 
and cognitive related quality of life scores.  
 
Correlations. 
Pearson product-moment correlations were computed between the adaptive functioning 
subscales (ASR) and the perceived cognitive and health related quality of life measures (FACT-
Cog and RAND-36 and subscales). 
 
Perceived cognitive related quality of life 
Positive correlations (p < 0.05, 2-tailed) between adaptive functioning and perceived cognitive 
related quality of life were found between the ASR- Mean adaptive T-scores and the FACT-Cog: 
Perceived cognitive abilities and Impact on quality of life. This indicated that reports of higher 
adaptive scores were associated with better perceived cognitive abilities and perceived impact of  
cognitive function on quality of life. In addition, significant negative correlations (p < 0.05, 2-
tailed) were also demonstrated between the ASR: Internalizing symptoms, Externalizing 
symptoms, and Total problems scales with the FACT-Cog: Perceived cognitive impairment, 
Perceived cognitive abilities, and the  Impact on quality of life. These correlations indicated that 
lower adaptive T-scores  (T-score < 60 suggests normal functioning) were associated with better-  
perceived cognitive abilities and perceived  impact of their cognitive function on quality of life. 
The results are presented in Table 32 
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Table 32. Correlation matrix between the ASR subscales and the FACT-Cog subscales  
  
ASR: Mean 
adaptive (> 
35 is normal) 
ASR: 
Personal 
Strengths (> 
35 is 
normal) 
ASR: 
Internalizing 
Symptoms 
(<60 is 
normal) 
ASR: 
Externalizing 
(<60 is 
normal) 
ASR: Total 
Problems (< 
60 is normal) 
FACT-Cog: Perceived 
cognitive impairment (/72) 
Pearson 
Correlation 
.414 -.003 -.645
**
 -.735
**
 -.798
**
 
Sig. (2-tailed) .098 .990 .005 .001 .000 
N 
17 17 17 17 17 
FACT-Cog: Comments 
from others (/16) 
Pearson 
Correlation 
.197 -.196 -.416 -.401 -.521
*
 
Sig. (2-tailed) .448 .452 .097 .111 .032 
N 
17 17 17 17 17 
FACT-Cog: Perceived 
cognitive abilities (/28) 
Pearson 
Correlation 
.617
**
 .329 -.617
**
 -.741
**
 -.730
**
 
Sig. (2-tailed) .008 .197 .008 .001 .001 
N 
17 17 17 17 17 
FACT-Cog: Impact on 
quality of life (/16) 
Pearson 
Correlation 
.712
**
 .275 -.789
**
 -.700
**
 -.816
**
 
Sig. (2-tailed) .001 .286 .000 .002 .000 
N 
17 17 17 17 17 
Note: * = p ≤ .05 (2-tailed), ** = p ≤ .01 (2-tailed) 
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Perceived health related quality of life 
Positive correlations (p < 0.05, 2-tailed) between adaptive functioning and perceived health 
related quality of life were found between the ASR- Mean adaptive score and all the health 
related scales; and the ASR- Personal strengths and the following RAND-36 subscales: Role 
limitations due to physical health, Energy/fatigue, Pain, and General Health subscales (RAND-
36 scores recoded such that greater z-scores indicate superior performance and less impairment). 
This indicated that with higher endorsement of adaptive qualities, the better participants 
perceived their health related quality of life in physical function, energy levels, pain perception, 
and general health. In addition, significant negative correlations (p < 0.05, 2-tailed) were 
demonstrated between the ASR: Internalizing symptoms, Externalizing symptoms, and Total 
problems scales with all the perceived health related subscales. These correlations indicated that 
with decreased endorsement of challenges (T-score < 60 suggests normal functioning), the better 
participants perceived their health related quality of life.  The results are presented in Table 33.  
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Table 33. Correlation matrix between the ASR subscales and the RAND-36 subscales  
 
  
ASR: Mean 
adaptive (> 35 
is normal) 
ASR: 
Personal 
Strengths (> 
35 is normal) 
ASR: 
Internalizing 
Symptoms 
(<60 is 
normal) 
ASR: 
Externalizing 
(<60 is 
normal) 
ASR: Total 
Problems (< 
60 is normal) 
RAND-36: Physical 
functioning  
Pearson 
Correlation 
.667
**
 .281 -.606
**
 -.498
*
 -.609
**
 
Sig. (2-tailed) .002 .259 .008 .035 .007 
N 18 18 18 18 18 
RAND-36: Role 
limitations due to 
physical health 
Pearson 
Correlation 
.664
**
 .531
*
 -.484
*
 -.499
*
 -.515
*
 
Sig. (2-tailed) .003 .023 .042 .035 .029 
N 18 18 18 18 18 
RAND-36: Role 
limitations due to 
emotional problems 
Pearson 
Correlation 
.654
**
 .349 -.552
*
 -.550
*
 -.641
**
 
Sig. (2-tailed) .003 .155 .018 .018 .004 
N 18 18 18 18 18 
RAND-36: 
Energy/fatigue 
Pearson 
Correlation 
.780
**
 .668
**
 -.880
**
 -.756
**
 -.867
**
 
Sig. (2-tailed) .000 .003 .000 .000 .000 
N 17 17 17 17 17 
RAND-36: Emotional 
well-being 
Pearson 
Correlation 
.686
**
 .332 -.874
**
 -.705
**
 -.846
**
 
Sig. (2-tailed) .002 .194 .000 .002 .000 
N 17 17 17 17 17 
RAND-36: Social 
functioning 
Pearson 
Correlation 
.729
**
 .344 -.763
**
 -.795
**
 -.846
**
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Sig. (2-tailed) .001 .177 .000 .000 .000 
N 17 17 17 17 17 
RAND-36: Pain Pearson 
Correlation 
.599
*
 .578
*
 -.537
*
 -.705
**
 -.651
**
 
Sig. (2-tailed) .011 .015 .026 .002 .005 
N 17 17 17 17 17 
RAND-36: General 
health 
Pearson 
Correlation 
.883
**
 .629
**
 -.901
**
 -.624
**
 -.806
**
 
Sig. (2-tailed) .000 .007 .000 .007 .000 
N 17 17 17 17 17 
Note: * = p ≤ .05 (2-tailed), ** = p ≤ .01 (2-tailed) 
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Inquiry 6. Explore relationships between adaptive function and  IQ.  
Correlations. 
Pearson product-moment correlations were computed between the ASR subscales and measures 
of Intelligence (WASI-Verbal IQ, WASI-Performance IQ, and WASI-Full Scale IQ), 
independently.  Positive correlations were found between the ASR: Mean Adaptive subscale and 
the WASI-Verbal IQ index. This indicated that increased endorsement of adaptive skills was 
associated with greater verbal abilities. In addition, negative correlations were demonstrated 
between the ASR: Internalizing, Externalizing, and Total problems subscales with all the 
measures of intelligence. These correlations indicated that decreased endorsement of symptoms 
was associated with greater cognitive function. The results are presented in Table 34.  
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Table 34. Correlation matrix between the ASR subscales and the WASI measures of Intelligence.  
 
  
ASR: Mean 
adaptive (> 35 
is normal) 
ASR: 
Personal 
Strengths (> 
35 is normal) 
ASR: 
Internalizing 
Symptoms 
(<60 is 
normal) 
ASR: 
Externalizing 
(<60 is 
normal) 
ASR: Total 
Problems (< 
60 is normal) 
WASI: Verbal IQ  Pearson Correlation .532
*
 .223 -.800
**
 -.705
**
 -.837
**
 
Sig. (2-tailed) .023 .375 .000 .001 .000 
N 18 18 18 18 18 
WASI: Performance 
IQ  
Pearson Correlation .400 .117 -.566
*
 -.523
*
 -.595
**
 
Sig. (2-tailed) .100 .644 .014 .026 .009 
N 18 18 18 18 18 
WASI: Full scale IQ  Pearson Correlation .464 .149 -.711
**
 -.678
**
 -.761
**
 
Sig. (2-tailed) .052 .555 .001 .002 .000 
N 18 18 18 18 18 
Note: * = p ≤ .05 (2-tailed), ** = p ≤ .01 (2-tailed) 
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Chapter 5: Discussion 
 
Part A: Neuropsychological profile 
In the present study we analyzed a sample of twenty emerging adults with low-grade glioma 
diagnosed in childhood. The sample was composed of twelve men and eight women, with a  
mean age at diagnosis of 10.8 years. At the time of testing, their mean education was 14.5 years. 
More than half the participants consumed medication at time of testing, were diagnosed with 
astrocytomas, had tumours located in the infratentorial region of the brain and resected by 
surgery, and experienced either seizures or hydrocephalus at the time of diagnoses.  Each 
participant completed a battery of neuropsychology tests in order to determine if the sample 
population’s long-term effects were homogeneous, and within the normal range compared to 
normative standards, or if group differences existed. In addition, the data were analyzed to 
explore differences in neuropsychological scores based on demographic and tumour related 
factors. The neurocognitive domains tested included: Intelligence, Memory, Visual Spatial skills, 
Motor skills, Attention, Executive skills, and Processing Speed.  
 
Our findings revealed a considerable degree of variation in the sample, ranging from good ability 
to relative deficits in function. Based on the performance of cognitive tests, the sample was 
divided into three subgroups, showing relatively mild, moderate, and severe levels of 
dysfunction. Group division was established by the number of measures below the average 
range, for example those with mild dysfunction had four or less scores below 1 standard 
deviation, those in the moderate group had five to ten scores below 1 standard deviation, and 
those in the severe group had 10 or more scores below 1 standard deviation (Ek, et al.,2005) .  
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Overall, participants in the subgroup with severe dysfunction showed widespread deficits in most 
cognitive domains compared to those in the mild subgroup. Differences between subgroups were 
found on measures of Intelligence, Memory, Processing Speed, and Executive functioning, with 
the severe subgroup performing worse than either moderate or mild subgroups.  We also found 
differences on neurocognitive measures for each of the following variables : education, age at 
diagnosis, medication consumption, time elapsed between diagnosis and testing, and tumour 
pathology. Below, I will consider the implications of the findings for each of the inquiry 
questions outlined in the results section, and discuss each of the findings with respect to the 
existing neuropsychological literature.  
 
Inquiry 1. Explore if differences exist in the sample population’s neuropsychological 
scores.  
Research investigating the heterogeneous nature of cognitive functioning in the glioma 
population has found significant differences between high- and low-grade gliomas (Chalil & 
Ramaswamy, 2016), with few studies investigating low-grade gliomas alone.  The differences 
between groups have been explained by diffuse insults to the brain due to the metastatic quality 
of the high grade gliomas compared to localized tumour growth in the low-grade populations 
(Ater et al., 1996).  
 
Our study evaluated low-grade gliomas in isolation from high-grade gliomas and determined that 
the sample population’s neuropsychological scores were heterogeneous, in that we found three 
subgroups based on neurocognitive scores. Similarly, Ek and colleagues (2005, 2010) analysed 
adults with low-grade gliomas diagnosed across the lifespan and also found three subgroups with 
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varying levels of cognitive disability termed severe, mild, and minimal selective dysfunction. 
The researchers divided the group based on performance below normal limits (i.e., below 1 
standard deviation) across eleven neurocognitive scores and based on dysfunction in processing 
speed (measured by Symbol Digit Modality: SDMT Oral and Written measures). The group with 
severe dysfunction had scores below normal limits for both SDMT trials and across measures of 
verbal memory, executive functioning, spatial reasoning, and intelligence, the second milder 
group had dysfunction in SDMT or in more than half of the variables, and the third group had 
normal performance in SDMT-Oral and in more than half of the other variables. Our study 
adopted the same subgroup terms as those of Ek and colleagues: however, our analyses 
demonstrated differences in the percentage of measures below the average range in each 
subgroup, whereby our subgroups demonstrated less dysfunction across thirty three measures of 
neurocognitive function as compared to those in Ek and colleagues. Nonetheless, outcomes on 
select cognitive measures from our study were consistent with those of Ek et al., with the 
majority of the subgroup in the severe  dysfunction group scoring below normal limits in both 
SDMT trials, while the minimal selective group displayed no difficulties in processing speed. In 
addition, similarities were found on tasks of Memory using the Rey Auditory Verbal Learning 
test (RAVLT) in the severe dysfunction subgroup, whereby we demonstrated consistent 
dysfunction in verbal learning, recall, and visual recognition. Although many similarities were 
found between our study and Ek et al. regarding the heterogeneity in neuropsychology scores, 
the most prominent difference was in the percentage of neurocognitive scores below normal 
limits. Ek and colleagues may have found more deficits in the group with severe disturbance due 
to their inclusion criteria and sampling data; age of diagnosis spanned childhood to adulthood (9-
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57 years old), included variability in education levels, and had a greater number of unemployed 
patients. 
 
The heterogeneous nature of the current sample refutes presumed notions that patients with low-
grade gliomas have uniform long-term neurocognitive outcomes when compared to norm 
referenced groups. Such assumptions have been bolstered in part because of high survival rates 
of pediatric low-grade gliomas, whereby patients whose tumours are completely resected have a 
survival rate of 90% or greater, 10 years from diagnosis (Sievert & Fisher, 2009). In addition, 
homogeneity has often been assumed because of favorable neurobehavioural outcomes, such as 
normative cognitive and adaptive functioning, although research over the last decade has 
demonstrated diverging results (Ris & Beebe, 2008). We established inter-individual differences 
when the group was sub-divided by their performance relative to normative standards, 
suggesting variable long-term neurocognitive sequelae.  A discussion of which outcome 
variables showed this heterogeneity is included in the consideration of Inquiry 2. 
 
Inquiry 2. Explore the inter-group variation on all neurocognitive measures. 
Following the group division established from Inquiry 1, we compared each group by 
neurocognitive measure. Results revealed no group differences on measures of attention, motor, 
and visual-spatial skills. In contrast, the severe subgroup performed lower than the other two 
subgroups on measures of intelligence (VIQ, PIQ and FSIQ), memory (visual and verbal recall), 
processing speed (written and oral mental speed), and executive function (mental flexibility). 
The results are somewhat consistent with a study conducted by Miotto and colleagues (2011). 
Much like other studies investigating cognitive deficits in brain tumour populations, they 
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investigated both high- and low-grade glioma patients. Their low-grade sample demonstrated 
specific deficits on verbal and visual memory recall, mental flexibility and processing speed, and 
no impairments in visual spatial and intellectual abilities. Miotto et al. evaluated patients prior to 
surgical removal of the tumour, which could suggest that patients who are candidates for surgery 
may have greater pre-surgical neurocognitive effects. To note, group differences were found on 
intelligence measures in our study and not in Miotto et al.’s study, possibly due to the method of 
group division rather than true intellectual deficits. In fact, the majority of our sample population 
performed within normal limits on all three measures of intelligence, yet the severe subgroup 
demonstrated significant differences from the moderate and mild  subgroups. Overall, the severe 
subsubgroup may represent a distinct sample in the low-grade glioma population whose 
demographic and tumour related factors may impact their long-term neurocognitive effects (this 
will be discussed in the General Discussion). Recent advances in neurobiology and 
histopathology over the last decade have discovered biological markers of gene mutations and 
aberrations that can lead to activation of further gliomagenesis (Tatevossian et. al, 2010) and are 
present in a subset of patients with pediatric low-grade gliomas. These biological markers may 
have been present in the severe subgroup in our study, but this information was not available in 
medical records during the period of data collection.  
 
Inquiry 3. Explore differences in neuropsychological scores based on demographic 
variables. 
Differences were found in neuropsychological scores based on specific demographic factors 
including education, age at diagnosis, medication consumption, and time elapsed between testing 
and diagnosis. No differences in neurocognitive functioning were found when sex was analyzed. 
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Sex differences in neurocognitive function are generally not found in the general population, 
although some studies document sex differences in brain organization resulting in superior 
performance for women when cerebral lesions are on the left, and in men when cerebral lesions 
are on the right (Yeo, 1983). In addition, children treated for brain tumours have shown a 
combination of demographic risk factors that contribute to declines in IQ following treatment 
including sex (women), younger age at diagnosis, and longer time since treatment. Our study 
may not have revealed sex differences in neurocognitive scores due to the small sample size 
resulting in the lack of specificity of associated risk factors.   
 
Not surprisingly, participants with post-high school education performed superior to those with 
less education on all three measures of intelligence (VIQ, PIQ and FSIQ). This finding is 
consistent with the general literature on intelligence and is not specific to the low-grade glioma 
population (Matarazzo & Herman, 1984). The pursuit of higher level education in the face of a 
brain insult during childhood is striking in this sample. This suggests that the majority of the 
sample was capable of pursuing their educational goals. A qualitative look at the subgroups in 
the present study revealed that the majority of participants in the severe subgroup had a high 
school education or less. The question then becomes whether the differential results on 
neuropsychological testing for this subgroup are related to education above and beyond the 
effects of the glioma.  
 
Another notable finding was that participants diagnosed at an older age (>10 years old) 
performed superior to those younger at diagnosis on measures of oral processing speed (SDMT- 
oral), motor skills (Purdue Peg board non dominant hand), and executive function (DKEFS 
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TMT- number sequencing). Younger age at diagnosis has been associated with impaired 
cognition on some variables including IQ, attention, and memory in brain tumour patients 
(Mulhern, et al., 2004; Pignatti et al., 2002). Taken together, these findings may support the 
notion that previously learned skills are retained prior to a brain insult (Palmer et al., 2001), such 
that brain injuries at a younger age carry a greater burden as fewer skills are developed and 
mastered by that point.  As such, younger patients have fewer skills to rely on during recovery 
and development.  In addition, larger tumours in younger patients have been found to more 
readily cause local mass effect with disruption of subcortical and cortical structures (Kaye, 
DeCarli, Luxenberg, & Rapoport, 1992) compared to older patients, which may also contribute 
to lower cognitive function.   
 
Similarly, we found that participants’ performance was superior in executive function (WCST) 
when fewer years had elapsed between testing and diagnosis. This result is somewhat 
confounded by age, such that those with shorter duration between diagnosis and testing were also 
older in age at diagnosis. Nonetheless, this finding is worth investigating to determine whether 
long-term residual effects exist following a low-grade glioma.  
 
Finally, medication consumption at the time of testing revealed significant differences across 
Intelligence, Memory, Motor skills, and Executive function. Overall, those on no medications 
performed better than those who were taking one or more medications.  Treatments ranged from 
pain medications (such as tegretol and nurofen), mood stabilizers (for example abilify), 
endocrine management (for example thyroxine) to anti-epileptic drugs (such as lamictal). It 
seems that the additional burden to manage medical complications, such as pain reduction or 
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mood stabilization, may impact the sample’s ability to meet normative standards on 
neuropsychological testing. Klein and colleagues (2003) determined that the use of anti-epileptic 
drugs (AEDs) in patients with low-grade gliomas was associated with significant reductions in 
information processing speed, psychomotor function, and executive function, but not in attention 
or memory. Furthermore, they reported that neuropsychological difficulties are aggravated by the 
severity of epilepsy and by the intensity of the treatment. Our analysis showed that medication 
consumption, irrespective of the type, was associated with lower performance, but further 
information about the levels of pain or symptom intensity would be important to know to make 
any definitive conclusions about the effects of medications on cognition in the population of 
those with gliomas.  
 
Inquiry 4. Explore differences in neuropsychological scores based on tumour related 
factors.  
Minimal differences were found in neuropsychological scores based on tumour related factors. 
We analyzed potential differences in tumour pathology, tumour location, treatment type, and 
symptoms at time of diagnosis. Participants with astrocytomas performed superior compared to 
those with other types of gliomas on measures of Executive Function (DKEFS verbal fluency 
and DKEFS TMT motor speed). This finding is in line with previous literature demonstrating 
favorable long-term outcomes for patients diagnosed with pilocyctic astrocytomas, whereas other 
gliomas have higher rates of diffusion and possible genetic aberrations leading to a potential 
deterioration of functioning (Camelo-Piragua & Kesari, 2016). It is worth nothing that our 
finding may be an artifact of sampling, since the two groups were quite unequal in size 
(astrocytoma n = 17, other gliomas n = 3).   
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It is well documented that children with low-grade gliomas have a high rate of long-term 
survival and do not often require the intensity of neurotoxic treatments used with higher risk 
pediatric tumours, including their high-grade glioma counterparts (Ris & Beebe, 2008). The 
predominant type of treatment to resolve low-grade gliomas includes surgical removal as the first 
step in management followed by adjuvant chemo- or radiation therapy (Schiff, 2015). Our 
findings did not demonstrate any differences between groups with surgery alone (n = 17) and 
those with adjuvant therapy (n = 3) on measures of neurocognitive function. This is in contrast 
with research that has indicated superior neurocognitive performance for patients who undergo 
surgery alone compared to those with adjuvant treatments (Surma-aho et al, 2001; Taphoorn et 
al, 1994). Yet, there is some evidence suggesting that neurocognitive deficits exist prior to 
surgery or toxic treatments as a consequence of the glioma itself (Cortes et al., 2011; Ek et al., 
2010). For example, Cortes and colleagues (2011) investigated neurocognitive functioning in 
patients with low-grade gliomas who were undergoing surgical resection. They found that over 
50% of the sample presented scores below the 40
th
 percentile in attention, language, visuo-
constructive skills, visual organization, language and executive functions. This may suggest that 
our results were non-significant between treatment groups since their functioning may pre-date 
their treatment protocols.  In comparison, other studies investigating the effects of radiotherapy 
in patients with low-grade gliomas have demonstrated that the tumour itself had the most 
deleterious effect on cognitive function and that radiotherapy resulted in additional long-term 
cognitive disability when high fraction doses were used (> 2 Gy) at six year follow up (Klein et 
al., 2002; Soffietti et al., 2010). A follow-up longitudinal study (range of 6-28 years from initial 
diagnosis) revealed that close to 50% of the patients who received radiotherapy (regardless of 
fraction dose) had more deficits in attentional functioning at the second follow-up (Douw et al., 
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2009). In addition, they found deterioration in executive functioning, information processing and 
attentional functioning between the first and second assessments for patients who had 
radiotherapy. This suggests that long-term survivors may develop progressive cognitive 
disabilities and are at risk of late toxicity of treatment which can impair cognitive functioning 
(Taphoorn & Neil, 2008; Moretti et al., 2001). It is unknown if our sample would have presented 
with changes in neurocognitive scores at a second-follow up session. In addition, the discrepancy 
between the sizes of the subsamples suggest caution in the interpretation of our findings. 
 
Our study revealed no differences in neurocognitive outcomes based on tumour location when 
analyzed based on divisions above and below the tentorium (sheet of dura matter separating the 
cerebrum from the cerebellum). This is in contrast to many studies that have revealed differences 
in tumour pathology and location, whereby some lesions lead to specific treatment regimens 
which predict more favorable neurocognitive sequelae.  For example, cerebellar and 
supratentorial astrocytomas are typically completely resected demonstrating few changes in 
cognitive functioning.  In contrast, most optic pathway/hypothalamic, deep midline, and brain 
stem gliomas have minimal potential for resection (Sievert & Fisher, 2009) and require 
combination chemotherapy and radiotherapy to improve survival rates, at the risk of 
neurocognitive, endocrine, and other possible long-term toxicities, as reported above.  Our 
sample did not have any participants with the latter set of gliomas and therefore we can speculate 
that although anatomical differences were present (infratentorial n =11, supratentorial n = 9), no 
neurocognitive differences based on location were found since the tumour pathology was similar.   
Furthermore, studies have documented both specific cortical locations and network-based 
connections (linking distant cortical regions together) responsible for domains of cognition 
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(Bartolomeo, 2011). Our sample size was unable to support such analyses, yet it is important to 
consider findings from the literature. Research suggests patients with lesions in the frontal lobes 
experience heightened cognitive impairment (Ek & Almkvist, 2010), whereas those with 
cerebellar lesions demonstrated lateralized cognitive deficits (Scott et al., 2001). Scott and 
colleagues (2001) researched pediatric tumours (not specific to low-grade gliomas) and found 
that damage in the right cerebellar structures was associated with verbal and literacy skill 
difficulties, whereas damage to the left cerebellar structures was associated with delayed or 
impaired non-verbal and spatial skills. These results support the notion that the learning and 
development trajectory can be offset as a result of a brain lesion.  
 
Finally, our study did not demonstrate neurocognitive differences between patients with the 
presence or absence of either hydrocephalus or seizures at the time of diagnoses. Seizures are a 
frequent comorbidity in pediatric brain tumour survivors and were present in more than 50% of 
our sample. Seizures are often a result of tumour pathology, cortical location, and subtotal 
resection (Ullrich et al., 2015). Studies investigating rapidly growing tumours such as those with 
high-grade gliomas have also revealed that cognitive deficits are more pronounced and 
widespread (Taphoorn & Niel, 2008) and can lead to hemiparesis or increased intracranial 
pressure (Ashby & Shapiro, 2004; Rees, 2002).   We can speculate that our sample did not 
demonstrate differences in neurocognitive functioning because the seizures were well-managed 
by medication following treatment.  
 
The neuropsychological profile revealed in our sample suggests heterogeneity in skills amongst 
the low-grade glioma population, whereby intelligence, memory, processing speed and executive 
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function are most impaired in the severe subgroup. Furthermore, participants’ performance was 
reduced with lower education levels, medication consumption, and younger age at diagnosis. The 
following chapter will shift the focus from objective measures of abilities to subjective 
perceptions of cognitive challenges and health related quality of life.  
 
Part B: Perceived Health and Cognitive Quality of Life 
The focus of the second set of inquires was the sample’s perceived health and quality of life. 
Each participant completed two questionnaires, the RAND-36 and the FACT-Cog, in order to 
determine whether there were domains of strengths and weaknesses, group differences, whether 
and associations between health and cognitive quality of life, and associations between objective 
measures of cognitive function and participants’ subjective experience. In addition, the data were 
analyzed to explore differences in measures of quality of life based on demographic and tumour 
related factors. The health related domains explored with the RAND-36 included: Physical 
functioning, Role limitations due to physical health, Role limitations due to emotional problems, 
Energy/fatigue, Emotional well-being, Social functioning, Pain, and General health. The 
cognitive domains investigated with the FACT-Cog included: Perceived cognitive impairment, 
Comments from others, Perceived cognitive abilities, and Impact on quality of life.  
Our findings revealed that the sample perceived their physical and general health favourably, and 
they showed positive perceptions of the impact of their cognitive functioning on quality of life. 
Differences were found between the sample’s perception of their physical health and social 
functioning, whereby social functioning appeared to be an area of relative weakness or concern. 
Inter-group variation, based on the cognitive subgroups established in Chapter 1 (Mild, 
Moderate, and Severe dysfunction), was found such that the Severe subgroup rated their physical 
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functioning, social functioning, and emotional well-being as more affected than the Moderate  
and Mild subgroups. In addition, the Severe subgroup endorsed more reports of  “(negative 
cognitive) Comments from others” than the Mild subgroup. Analyses of the demographic and 
tumour related factors on perceived quality of life showed effects of sex, education, and 
medication consumption. Positive associations were revealed between perceived health and 
cognitive quality of life. In addition, the sample demonstrated that their subjective abilities were 
in line with their objective performance on measures of cognitive function.   
 
Inquiry 1. Identify domains of strengths and weaknesses in the sample population’s 
perceived health and cognitive quality of life.   
Our findings identified areas of strength and challenges based on the questionnaires completed. 
A third or greater of the sample reported few challenges with Physical functioning, Role 
limitations due to physical health, Energy/Fatigue, Pain, and General health. Interestingly, 
General health was also an area of concern for our population whereby a third of the sample 
reported scores below the normal range (< 1 standard deviation). In addition, forty percent of the 
sample reported no identifiable challenges with cognitive functioning. The sample perceived 
their physical functioning and their lack of  role limitations due to physical health as superior to 
their social functioning. Social functioning has been explored in the brain tumour literature as 
ability secondary to emotional perception in interpersonal relationships and social cognition. 
Researchers have theorized that patients with gliomas may preserve or maintain their social and 
professional relationships due to compensatory mechanisms of multi-sensory emotional 
integration abilities (Boullay et al., 2014). Our findings of reduced perceived social functioning 
might suggest that although the sample could maintain a level of social integration, they 
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perceived this area as a challenge. Unlike our study, Taphoorn and colleagues (1994) 
demonstrated that long-term survivors of low-grade gliomas suffered more frequently from 
fatigue and depressed moods than controls. It is well documented that high-grade glioma 
populations report concerns of uncertainty regarding prognosis (terminal malignancy) and 
quality of life, dependence on carers due to cognitive deficits, increase in neurological deficits, 
and the inability to resume daily activities (Halkett, et al., 2010; Dogel et al., 2004). Unlike high-
grade glioma populations, our low-grade sample reported favorable perceived quality of life, 
possibly due to limited threats of mortality compared to a high-grade diagnosis. In addition, most 
studies that combine both groups (malignant and benign tumours) demonstrate worse quality of 
life in dimensions of physical, functional, family, social, and overall perception of well-being 
(Cortes & Crespo, 2015; Munoz et al., 2008). Similarly, we found reduced social functioning and 
endorsements of challenges in general health in a proportion of the sample. In comparison, our 
study demonstrated superior perceived physical functioning and general health. The differences 
found between studies emphasize the need for independent research for the low- and high-grade 
glioma populations. 
 
Inquiry 2. Explore the inter-group variation in the quality of life questionnaires.  
Following the group division established from Chapter 1; Inquiry 1, we compared each group on 
the quality of life subscale. Results revealed group differences on measures of Physical 
functioning, Social functioning, and marginally on Emotional well-being, and (cognitive) 
Comments from others, whereby the Severe subgroup rated their functioning lower than the 
other two subgroups. Our findings are consistent with research conducted by Ediebah and 
colleagues (2016), who explored the impact of patient-proxy agreement on documented 
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neurocognitive deficits on the Rand-36 and EORTC QLQ-BN20 in patients with low-grade 
gliomas. They discovered that the subgroup deemed to have cognitive impairments reported 
poorer physical functioning than did their proxies, whereas no differences emerged between 
patient and proxy reports in the cognitive intact group. This may suggest that our Severe 
subgroup’s response style is impacted by their cognitive challenges. This has also been shown 
with high-grade glioma patients in that the concentration required to evaluate each statement on a 
questionnaire and then make a decision sometimes proves too demanding on the patient (Lyons, 
1996). Alternatively it could be that the Severe subgroup’s perceptions represent their true 
beliefs of reduced quality of life.  
 
Inquiry 3. Explore differences in perceived quality of life scores based on 
demographic variables.  
Differences were found in perceived quality of life measures based on specific demographic 
factors including sex, education, and medication consumption. No differences in measures were 
found when age at diagnosis, and time elapsed between testing and diagnoses were analyzed. 
Women reported more challenges on emotional well-being than men. Previous studies have not 
found an effect of sex on self-reports making, the present findings unusual and in need of 
replication before strong conclusions can be made. Secondly, participants with post-high school 
education rated their functioning more favourably than those with less education on 11 out of the 
12 subscales across health and cognitive quality of life. Lower education has been found to be an 
indicator associated with multiple domains of distress, poor quality of life and high unmet needs 
in the high-grade glioma population (Halkett, et al., 2015).  Lastly, the group with an absence of 
medication consumption reported greater functioning in the following subscales: Physical 
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functioning, Energy/Fatigue, Emotional well-being, Social functioning, General health, and the 
(cognitive) Impact on quality of life. The effect of medication consumption was surprising given 
the range of medications consumed by our sample. We suspect that chronic medication use, 
regardless of the type or dose, impacts participant’s perception of their abilities and quality of 
life.  
 
Inquiry 4. Explore differences in perceived quality of life scores based on tumour 
related factors.  
No differences were found in perceived quality of life measures based on tumour related factors. 
We analyzed potential differences in tumour pathology, tumour location, treatment type, and 
symptoms at time of diagnosis, and found no effects of any of these variables on reported quality 
of life. Previous studies have found reduced reported quality of life for glioma patients with 
uncontrolled intractable epilepsy (Vercueil, 2011; Maurice & Mason, 2014; Klein, et al., 2003), 
greater tumour size, and tumours in the right side or anterior region (Salo et al, 2002). 
Differences in findings between the literature and our study might be a result of the mixed 
malignancy samples, i.e., malignant and benign tumours, with those with malignant tumours 
lending more weight to the outcomes of prior studies.  Interestingly, some researchers have ruled 
out radiotherapy as adversely impacting quality of life in long-term survivors of low-grade 
gliomas (Taphoorn et al., 1994; Petz et al., 2001).    
 
Inquiry 5.  Explore relationships between perceived cognitive and health related 
quality of life scores.  
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Correlations between perceived health (RAND-36) and cognitive related quality of life (FACT-
Cog) revealed positive associations between most of the subscales, excluding measures of Pain, 
and Role limitations due to physical health. More specifically, significant associations with most 
of the RAND-36 were found with the Perceived cognitive impairments, Perceived cognitive 
abilities, and Impact on quality of life on the FACT-cog. The Comments from others subscale on 
the FACT-cog was positively associated with the Physical functioning, Emotional functioning, 
and Social functioning subscales on the RAND-36. Our findings suggest that superior cognitive 
perceptions are associated with greater perceived health-related quality of life. No literature 
exists on the relationship between cognitive and health-related quality of life. We speculate that a 
meaningful bi-directional relationship exists between health and cognitive perceptions whereby 
one perception impacts the other. For example, greater perceptions of one’s cognitive abilities 
may result in greater community involvement, the pursuit of education or employment, and 
enjoyment in relationships – all aspects endorsed in greater perceptions of quality of life.   
 
Inquiry 6. Explore relationships between perceived quality of life scores and IQ.  
Correlations between the perceived health quality of life scores and measures of cognitive 
function demonstrated significant positive associations between both verbal and performance IQ 
with the following subscales of the RAND-36: Physical functioning, Social functioning, 
Emotional functioning, and General Health.  Verbal IQ was additionally positively correlated 
with Energy/fatigue whereas the association with Performance IQ approached significance. The 
results indicated that an increase in objective verbal and performance abilities is associated with 
superior perceived physical, social, and emotional functioning.  
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Results from the correlations between the perceived cognitive quality of life scores and measures 
of IQ demonstrated significant positive associations between both verbal and performance IQ 
with the following subscales from the FACT-Cog: Perceived cognitive impairment, Comments 
from others, and Impact on quality of life. Similar to the findings above, Verbal IQ was 
additionally positively correlated with Perceived cognitive abilities whereas the association with 
Performance IQ approached significance. These results indicate that an increase in objective 
verbal and performance abilities are associated with superior perceived cognitive abilities, fewer 
perceived impairments, and a favorable cognitive impact on their overall perceived quality of 
life.  
 
Similar to Inquiry 5, there is a paucity of research on associations between objective and 
subjective cognitive abilities in the glioma literature. In addition, there appears to be an absence 
of research on the associations between objective abilities and perceived quality of life. In 
contrast, there is evidence for decreased cognitive status and quality of life in the low-grade 
glioma population (Reijneveld et al., 2001), although it is unknown if previous studies found 
correlations between the two measures. One study evaluating objective and subjective measures 
of cognitive function in breast cancer patients, using the FACT-Cog, determined that measures 
of objective and subjective cognitive function both declined over the course of chemotherapy but 
there was no significant relationship between these variables (O’Farrell, Smith, & Collins, 2016). 
In comparison, Von and colleagues (2010) found the Perceived cognitive impairment and 
Perceived cognitive abilities subscales were correlated with selective cognitive measures in a 
sample of breast cancer survivors. Similarly, the FACT-Cog was administered in parallel with a 
neuropsychological assessment with patients following hematopoetic stem cell transplantation. 
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Findings in this patient sample revealed no significant correlation between the FACT-Cog 
scores, with the exception of one subscale, Comments from others, with cognitive performance 
(Jacobs et al., 2007).  In contrast, we found all the subscales of the FACT-Cog except Comments 
from others to be correlated with objective measures of cognitive function, similar to findings 
from a broad range of cancer patients following chemotherapy treatment (Lange et al., 2016). It 
is not surprising that differences exist between the populations outlined above and our sample, 
but it highlights the need for more research into this area with the glioma population, in 
particular exploring sensitivity of the measures between populations. Furthermore, a number of 
studies have indicated the necessity of evaluating subjective experiences of quality of life in 
addition to neuropsychological evaluation in order to addresses specific concerns from patients 
(Moritz-Gasser & Duffau, 2010), yet to date limited data exist.   
 
Part C: Measures of Adaptive Functioning 
The third area explored in the study involved measuring the sample’s adaptive functioning. Each 
participant completed the Adult-Self Report (ASR), in order to determine whether there were 
domains of strengths and weaknesses, if group differences existed, whether health and cognitive 
quality of life were associated, and if objective measures of cognitive function relate to 
participant’s adaptive abilities. In addition, the data were analyzed to explore differences in 
measures of adaptive function on demographic and tumour related factors. The adaptive 
measures explored on the ASR included: Mean adaptive abilities, Personal strengths, 
Internalizing symptoms, Externalizing symptoms, and Total problems. Our findings revealed that 
the majority of the sample reported normal adaptive functioning.  No strengths or weaknesses 
were found between the subscales, although the sample was divided on participants’ report of 
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internalizing symptoms. Inter-group variation, based on the cognitive subgroups established in 
Chapter 1 (Mild, Moderate, and Severe) was found such that the Severe subgroup reported more 
difficulties in externalizing symptoms and overall symptoms (aggregate of externalizing and 
internalizing symptoms) than the Selective subgroup. Upon analysis of the demographic and 
tumour related factors on adaptive function, we found differences in adaptive functioning 
according to sex, education, and medication consumption. Significant associations were revealed 
between the adaptive measures and perceived health and cognitive quality of life. In addition, 
higher adaptive abilities were associated with greater cognitive function. The subsequent 
discussion follows the inquiry questions outlined in the Results section and will compare our 
findings with the literature. 
 
Inquiry 1.  Identify domains of strengths and weaknesses in the sample population’s 
adaptive functioning. 
Our findings revealed evidence for positive adaptive functioning in our sample. Greater than half 
of the sample rated items in the normal range (based on normed standard T-score cut offs) across 
the four areas of adaptive functioning: Mean adaptive, Personal strengths, Internalizing 
symptoms, and Externalizing symptoms. No differences were found between the four scales 
suggesting equivalent functioning across the domains, yet the Personal strengths scale was 
endorsed most favorably by the majority of the sample (83%). This scale reflected perceptions of 
responsibility, honesty, fairness and equitable treatment of others. In comparison, a proportion of 
the sample (45%) rated items in the borderline or clinical range on the Internalizing scale. The 
most frequent symptoms endorsed on the Internalizing scale were within the Anxious/Depressed 
subscale, with fewer in the Somatic complaints and Withdrawn subscales. Item analysis revealed 
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concerns related to lacking in self-confidence, having worries about their future and their 
presentation to the opposite sex, and experiencing feelings of fear of success, nervousness, 
sadness, self-consciousness, worthlessness and being lonely. The somatic complaints endorsed 
included feeling tired, experiencing sleeping disturbances, and aches and pains.  Our findings of 
increased internalizing symptoms are in line with the literature demonstrating that the low-grade 
glioma population suffers more frequently from depressed mood when compared to the general 
population (Taphoorn et al., 1994; Petz, et al., 2001; Boele et al., 2014). In addition, with the 
greater endorsement of anxiety, it appears that the type of anxiety experienced between newly 
diagnosed low-grade gliomas (i.e., fear of morbidity from the intervention, Hayhurst, 
Mendelsohn, & Bernstein, 2011) and long-term survivors differs; yet it is unknown if anxiety 
evolves from one time period to the next.  
 
Inquiry 2. Explore the inter-group variation across the adaptive measures.  
Following the group division established from Chapter 1; Inquiry 1, we compared each group on 
the adaptive functioning subscales. Results revealed marginal subgroup differences on measures 
of Externalizing symptoms, and Total problems; whereby the Severe subgroup reported more 
challenges than the Mild dysfunction subgroup. The Total problems scale is an aggregate of the 
Externalizing and Internalizing scales, and therefore reflects that the sample endorsed difficulties 
in both domains. Item analyses within the Externalizing scale demonstrated a frequent 
endorsement of statements within the Aggressive subscale and fewer in the Rule-breaking and 
Intrusive subscales. Common items endorsed included themes of quick mood changes, stubborn 
personality, easily upset, argumentative, socializing with bad friends, lacking responsibility, 
acting on impulse, showing off, and being loud. This suggests that it is worthwhile to further 
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investigate differences between cognitive functioning subgroups to determine not only the 
presence of internalizing symptoms, but also externalizing symptoms. Furthermore, findings 
from both tumour populations  (Ris & Beebe, 2008) and non-clinical populations have shown 
comorbidity between internalizing and externalizing symptoms and low cognitive functioning 
(Dietz et al.,1997; Goodman, 1995).  
 
Inquiry 3. Explore differences in psychological adaptive functioning measures based 
on demographic variables.  
Differences were found within the same demographic factors for adaptive measures as were 
demonstrated with perceived quality of life measures in Chapter 2; these included sex, education, 
and medication consumption. No differences in measures were found when age at diagnosis and 
time elapsed between testing and diagnoses were analyzed. In comparison, shorter elapsed time 
has been found to be related to greater depressed moods in the low-grade glioma adult 
population (Mainio et al., 2006). Results from our analyses revealed that women reported more 
challenges in internalizing symptoms and total problems than men. Secondly, the subgroup with 
less education (High school diploma or less) reported more difficulties in internalizing and 
externalizing symptoms. In addition, their mean T-scores were within the clinically borderline 
range across all domains. It is possible that this finding is confounded by other factors including 
lower cognitive level and health. Lastly, the subgroup consuming medications at the time of 
testing reported greater challenges across all domains except externalizing symptoms. 
Furthermore, their mean T-scores in the Internalizing and Total symptoms scales were also 
within the clinically borderline range. This suggests that medication consumption, regardless of 
the class of drug (mood stabilizer, anticonvulsant, pain and allergy medications), may create 
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more vulnerability to internalizing behaviours. Furthermore, there was no reason to suspect that 
this sample was self-medicating.   
 
Inquiry 4. Explore differences in psychological adaptive functioning domains based 
on tumour related factors.  
No differences were found in psychologically adaptive function measures based on tumour 
related factors. We analyzed potential differences in tumour pathology, tumour location, 
treatment type, and symptoms at time of diagnoses. Laterality has been shown to affect anxiety 
symptoms whereby primary tumours in the right hemisphere have been associated with increased 
anxiety prior to surgery than left hemisphere tumours. In addition, only right hemisphere 
tumours were associated with a decline of anxiety levels following tumour removal to that of the 
general population (Mainio et al., 2003). In contrast, our long-term survivor sample did not show 
any evidence of tumour related factors for internalizing symptoms. It is possible that no effects 
were noted due to the small sample size and the distribution of tumour factors in our sample. For 
example, tumour pathology was grouped as astrocytoma (n = 17) and “other gliomas” (n = 3) 
which included ependymomas, oligodendrogliomas, and gangliogliomas. This distribution can 
prove challenging to uncover differences between tumour pathology because of sample size and 
subgroup inclusion.  
 
Inquiry 5. Explore relationships between adaptive functioning and perceived health 
and cognitive related quality of life scores.  
Significant correlations between the adaptive domains on the ASR and the two perceived quality 
of life measures (FACT-Cog and RAND-36) were found. To begin, the ASR- Personal strengths 
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subscale was not correlated with any of the FACT-Cog subscales. We can speculate that 
individuals rated their perception about their rights and values favourably regardless of their 
perceived cognitive function.  Secondly, the ASR- Mean adaptive score was positively 
associated with the FACT-Cog- Perceived cognitive abilities and Impact on quality of life. The 
Mean adaptive scale reflects individuals’ reflection on how they function with their friends, 
spouse/partner, family, job, and education. It is thus reasonable to interpret the positive 
association as demonstrating that greater functioning in multiple social and domestic areas is 
related to greater perceived cognitive abilities. In contrast, findings from Khelifa-Gallois and 
colleagues (2015), exploring functional outcomes in adolescents and adults treated for a low-
grade cerebellar astrocytoma in childhood, found close-to-normal academic achievement and 
normal autonomy, despite a high rate of reported cognitive difficulties. Differences in findings of 
perceived cognitive function relate predominately to the measurements used, such that they tap 
into different aspects of adaptive abilities.   Furthermore, both Internalizing and Externalizing 
subscales on the ASR were inversely correlated with the following subscales on the FACT-Cog: 
Perceived cognitive impairment, Perceived cognitive abilities, and Impact on quality of life. This 
indicates that reports of fewer internalizing and externalizing symptoms are associated with 
superior perception of cognitive functioning. Our findings were in line with previous literature 
documenting significant associations between the FACT-Cog subscales with anxiety and 
depression (Lange et al., 2016) in a diverse cancer survivor population. In addition a decline in 
perceived cognitive function has been shown to be associated with greater anxiety, fatigue, and 
depressive symptoms in samples of breast-cancer survivors (O’Farrell, Smith, & Collins, 2016; 
Von Ah & Tallman, 2015).  
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The ASR was subsequently correlated with measures from the RAND-36 revealing significant 
associations. The ASR- Mean adaptive subscale was positively correlated with all eight measures 
of perceived health related quality of life. This again demonstrated that greater functioning in 
multiple social and domestic domains were associated with a greater perception of quality of life. 
Similarly, the ASR-Internalizing and Externalizing symptoms scales were inversely correlated 
with all eight measures of perceived health related quality of life. This indicated that reports of 
less internalizing and externalizing symptoms were associated with greater perceptions of quality 
of life. This association has been documented across the literature with both the low-grade 
glioma and survivors of tumours of the central nervous system. Most studies report a decrease in 
quality of life associated with low mood and the presence of clinical manifestations of depression 
(Cortes & Crespo, 2015; Warren, 2015; Taphoorn et al., 1994; Noll et al., 2015). In addition, 
some studies demonstrate that the low-grade glioma population suffers more frequently from 
depressed moods (Taphoorn et al., 1994; Petz, et al., 2001). Evidence of externalizing symptoms 
and other internalizing symptoms beyond depression, anxiety, and fatigue has not been shown in 
the literature. Finally, the ASR- Personal strengths subscale was positively correlated with the 
following RAND-36 subscales: Role limitations on physical health, Energy/fatigue, Pain, and 
General Health. This demonstrated that greater reports of positive self-attributes were associated 
with fewer limitations on physical health, energy and fatigue, pain, and general health. This 
finding is not surprising in that those who have positive attitudes tend to report greater physical 
well-being. Evidence of this relationship has been found in siblings of those with chronic health 
conditions whereby they had lower self-attributes and greater challenges in quality of life than 
controls (Vermaes et al., 2012).  
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Inquiry 6. Explore relationships between adaptive function and IQ.  
Correlations between the adaptive domains and measures of cognitive function demonstrated 
significant positive associations between Verbal IQ and the Mean adaptive subscale, indicating 
that an increase in verbal abilities is associated with greater endorsement of functioning across 
social and domestic domains. In addition, both verbal and performance IQ were inversely 
associated with internalizing and externalizing symptom scales. This indicated that greater 
cognitive function was associated with fewer endorsements of internalizing and externalizing 
symptoms. This result is consistent with the body of knowledge suggesting that IQ is a protective 
factor against psychopathology.  For example, a systematic review undertaken by Francis and 
colleagues (2016) demonstrated that gifted children exhibit superior socio-emotional adjustment 
and fewer behavioural difficulties than their typically developing peers.   
 
Summary of Key Conclusions across the Three Inquiries 
This study has provided information of clinical significance, particularly for the lower cognitive 
functioning subgroup of survivors of low-grade glioma. While the majority of the participants in 
our study fell within the average range for most cognitive tasks, there was variability on test 
scores that was used to identify three subgroups. The subgroups demonstrated differences in 
perceived quality of life and adaptive function.  As a whole, the lower cognitive functioning 
subgroup (i.e., “Severe” subgroup) experienced challenges on tasks of memory, processing 
speed, and executive functioning, in line with findings from Ek and colleagues (2005). In 
addition, the lower cognitive functioning subgroup reported greater challenges in perceived 
physical health, physical, social, and emotional well-being, and internalizing and externalizing 
symptoms. Returning to Dennis’s model of the relationship between medical disorder and 
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outcome, we can postulate that the variability in cognitive phenotype demonstrated between the 
groups could be attributed to differences in biological risk, whereby the “Severe” group could be 
categorized as “High biological risk” thus crossing the threshold of impairment into the 
subclinical range on high challenge tasks. In comparison, the “Mild” and “Moderate” subgroups 
demonstrated selective impairments suggesting that they were buffered from risk and categorized 
as “Low biological risk”. Individuals in the latter subgroups appeared protected from clinical 
impairment on most high challenge tasks. Core deficits were not revealed in our sample of 
glioma patients as performance on neurocognitive, perceived quality of life, and adaptive 
behaviour measures varied across various levels of disorder severity and mental ability.  
 
Dennis’s model further suggests that the child’s development, time since onset, and reserve 
available in the child, family, school, and community can contribute and moderate the risk 
outcome based on the strength of the valence of each factor, whereby negative factors (such as 
developmental delays, early age of onset, and less reserve) exacerbate risk and positive factors 
(such as average to above average premorbid IQ, later age of onset, and more reserve/support) 
protect from risk. Our findings generally support this model. Medication consumption, 
understood as a secondary effect of the brain tumour, was demonstrated to be linked with an 
increased biological risk on neurocognitive measures, perceived quality of life and adaptive 
functioning.  This suggests that an ongoing health condition requiring treatment (e.g., seizures, 
pain, psychiatric, etc), captured by “medication consumption” may be driving these results. 
Effect of age and developmental level at disorder onset were demonstrated, whereby older age at 
onset was deemed a protective factor for neurocognitive functioning.  Time since onset was 
demonstrated to relate to a single measure of executive functioning, whereby fewer years elapsed 
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between diagnosis and testing emerged as a protective factor. The final moderator, reserve in the 
child as documented by pre-insult status and social environment or opportunities, was 
demonstrated to buffer the impact of the disorder across neurocognitive, perceived quality of life, 
and adaptive functioning, namely sex and education level. Factors not studied in the current 
exploration, including family resources, such as socioeconomic status, family mental health, and 
psychosocial opportunities may have additionally exacerbated or buffered vulnerability to 
neurocognitive function, psychopathology, and perceived quality of life.   
 
The moderators of risk were categorized as either demographic or tumour related factors and 
some revealed noteworthy results, albeit each factor was analysed independently from one 
another. As mentioned above, medication consumption (related to ongoing health conditions 
requiring treatment) was linked with greater biological risk in our sample whereby participants 
consuming medications had lower measures of IQ, visual memory, delayed verbal memory, 
executive functioning, and motor skills.  In addition, they reported decreased perceptions of their 
health and cognitive quality of life and clinically borderline levels of internalizing symptoms. No 
neurocognitive differences were found by sex; however women perceived reduced effectiveness 
in their emotional well-being, and greater challenges with internalizing symptoms. Older age at 
diagnosis was related to superior performance in measures of processing speed, motor skills, and 
executive functioning, with no evidence of differences in adaptive and quality of life measures.  
 
Academic achievement was determined to be a significant moderating factor, in line with Stern’s 
cognitive reserve model (Stern, 2002) and Dennis’s pediatric medical model (2000), whereby our 
study demonstrated that less education was related to lower levels of intelligence, decreased 
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perceptions of health and cognitive quality of life, and reports of clinically borderline levels of 
internalizing and externalizing symptoms. Objective measures of intelligence were positively 
associated with subjective perceptions of cognitive and health related quality of life and adaptive 
functioning.  
 
Few differences were found between the tumour related factors on measures of neurocognitive 
functioning, perceived health and cognitive quality of life, and adaptive functioning. With 
greater sample sizes we would expect treatment related differences to emerge in emotional 
adjustment, social functioning, and intelligence as was documented by Ris and Beebe (2008) 
with adult survivors of pediatric low-grade gliomas.  
 
Overall, the sample perceived their health and cognitive quality of life as satisfactory, although 
they reported the greatest differences between physical and social functioning, whereby social 
functioning was a relative weakness. We can speculate that social competence is considered a 
challenging skill for this group as it can be independently moderated by settings of development, 
time and reserve. As such, we may suggest that those with low biological risk are not effectively 
buffered from challenges in social functioning in comparison to effective buffering when faced 
with neurocognitive challenges.  Similarly, the majority of participants endorsed adaptive 
function in the normative range with the exception of internalizing symptoms. Just less than half 
of the participants reported internalizing challenges in the borderline to clinical range endorsing 
symptoms of anxiety, depression, somatic complaints, and feelings of withdrawal.  
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Lastly, associations were found between the adaptive functioning subscales and measures of 
perceived health and cognitive quality of life.  Greater challenges in externalizing and 
internalizing symptoms, also termed post-injury psychopathology, were associated with an 
increase in perceived cognitive impairments, perceived reduction in cognitive abilities, and 
difficulties across all domains measured of health related quality of life. This finding 
demonstrated the bi-directional nature of the interactions among resources documented in 
Dennis’s risk-outcome framework, such that one confounds the other.  
 
 
Limitations 
It is unknown whether the results identified in this study were due to specific characteristics of 
the sample, the research methods utilized in the study, or whether the measures used were 
sensitive to detecting meaningful effects. The clinical sample size was small, although it yielded 
significant results across the cognitive, perceived quality of life, and adaptive domains. Small 
sample sizes are typical in clinical studies and come with known methodological disadvantages. 
In our sample we were limited to the data gathered such that the majority of the sample 
underwent surgery alone and had a diagnosis of pilocytic astrocytoma. We therefore had limited 
variability in treatment type and tumour pathology and thus the results were interpreted with 
caution. In addition, upon consultation with statisticians, we were advised that multiple 
regression analyses would yield inaccurate results. As such, we were unable to determine the 
variance explained by each demographic and tumour related predictor; instead, we analysed each 
factor independently, with the understanding that there would be shared unexplained variance. 
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The cognitive tests used, even when designed to test a specific cognitive domain, often require a 
number of skills. This makes it difficult to isolate one precise skill that may be impacted. For 
example, the executive functioning tasks often require memory, attention, visual and or verbal 
skills in order to achieve success. Similarly, the quality of life and adaptive measures require 
additional abilities beyond simply endorsing statements; which may include sustained attention, 
self-reflection, and decision making. These additional skills may have impacted our participants 
such that we had some incomplete questionnaires, resulting in absent data.   
 
Lastly, the study was designed as a cross-sectional study investigating late effects, yet it required 
retrospective investigation of medical records in order to determine eligibility, and specific 
tumour related factors. As such we were limited by the information provided in the documents 
and thus were restricted in selecting our variables of interest. For example, we investigated 
differences between supra- and infra-tentorial tumour locations rather than by hemispheres, 
lobes, anterior or posterior position, and laterality.  
 
Future Directions 
Investigations of the long-term effects of neurocognitive and adaptive functioning in the low-
grade glioma population have revealed differences compared to normative samples, yet this area 
of research is scarce in the literature. More data need to be collected and verified in larger 
cohorts of long term survivors of low-grade gliomas, such that demographic and tumour related 
factors can be analysed. Larger sample sizes would also increase diversity in treatment type, 
tumour pathology and histology, which were limitations we encountered in our sample. In 
addition, knowledge of neurocognitive and adaptive skills pre-insult, at the time of diagnosis, 
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and during the acute phase of recovery, in addition to the long-term effects, would bolster our 
understanding of how symptom presentation changes over the course of recovery and 
survivorship.  
 
This study was cross-sectional, and as such provided a brief snapshot of the participant’s 
functioning and perception at one particular point in time. Since there were no baseline 
measurements, it is unknown whether their current functioning represented a change in 
trajectory. Future research should gather longitudinal data to provide better estimates of the 
prevalence of long-term effects, and the extent to which these affect everyday functioning.  It 
would be important to gain more information on the presence and evolution of these symptoms, 
in particular with patients presenting with lower cognitive functioning. In addition, follow-up 
clinical care for this diverse group of survivors is necessary to address potential long-term effects 
as they arise. Clinical care for the low-grade glioma population could resemble the 
neuropsychological care of patients with cancer related neurocognitive dysfunction , whereby 
they receive 1) a neuropsychological assessment, 2) monitoring of neuropsychological 
functioning, 3) treatment recommendations for cognitive, emotional, and behavioural 
impairments based on neuropsychological evaluation outcomes, 4) educational support to the 
patient and family, and 5) monitoring of the effectiveness of interventions to improve 
functioning.  
 
Self-report measures were a valuable tool in accessing survivors’ perceptions of their quality of 
life and adaptive functioning. An additional area of future study is the relationship between 
patient-proxy and self-reports. Patient-proxy reports would be an asset to complement self-
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reports of cognitive function, quality of life, and adaptive function. Comparisons between the 
reports would add to our understanding of how patients and their support network perceive their 
abilities in order to provide accurate care to both patient and family.  
 
Conclusion 
Our study has provided further evaluation of the long-term effects in survivors of low-grade 
gliomas. Unlike other studies, our sample included a select subset of central nervous system 
tumour survivors in order to evaluate potential strengths and weaknesses and to assess 
demographic and tumour related factors pertinent to this group. Compared to other studies, we 
evaluated several domains of neurocognitive function, which revealed heterogeneity in the group 
and identified an important lower functioning subgroup relative to the other participants.  
Following Dennis’s pediatric risk-outcome model, it is likely that the cognitive phenotype found 
in our sample of low-grade glioma participants is a result of not only the tumour itself, but an 
expression of biological risk moderated by the child’s development, the time since onset of the 
tumour, and the reserve available within the child, family, school, and community.  
The protective moderators of risk identified in our study included older age at diagnosis, absence 
of medication consumption (i.e., absence of an ongoing health condition requiring treatment), 
and high academic achievement. We were unable to thoroughly assess tumour related variables 
due to the small sample size, although we can speculate that high doses of radiation therapy and 
chronic symptoms such as a seizure disorder would be linked to lower neurocognitive function. 
In addition, compromised neurocognitive function for the majority of the sample was spared 
which may be explained by threshold theories of outcome whereby individuals can be buffered 
from impairment. In this case, the slow-growing nature of low-grade gliomas may have shielded 
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risk resulting in a greater buffer zone compared to other medical conditions, namely high-grade 
gliomas. Investigating changes in cerebral white matter volumes may help to explain this 
phenomenon in relation to our findings of neurocognitive diversity in the sample.   
 
Furthermore, our use of subjective measures of cognitive function, adaptive function, and quality 
of life has highlighted the need for further research into survivors’ experience. The self-report 
measurements used in the study revealed important clinical information which was a novel 
approach in the study of survivors of low-grade gliomas. We discovered that the sample 
endorsed difficulties in adjustment in both internalizing and some externalizing symptoms, and 
strengths in self-attributions, and perceived health and cognitive quality of life. It is hoped that 
the current study will enhance the understanding of the impact that pediatric low-grade gliomas 
have on emerging adulthood and result in added follow-up neuropsychological and 
neurobehavioural care.  
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Appendix A. Table of sample size of each measure administered.  
 
Measures 
 
N 
 
Neurocognitive Measures 
 
 
WASI: verbal IQ  20 
 
WASI: performance IQ  20 
 
WASI: full scale IQ  20 
 
WAIS-3: digit span scaled score 20 
 
WAIS-3: digit span  20 
 
Rey-complex figure: immediate recall 20 
 
Rey-complex figure: delayed recall 20 
 
Rey-complex figure: recognition correct 20 
 
RAVLT: trial 1 (immediate recall) 19 
 
RAVLT: total recall 19 
 
RAVLT: trial 8 (delayed recall) 19 
 
RAVLT: recognition list A  19 
 
RAVLT: recognition list B  19 
 
SDMT: written  19 
 
SDMT: oral  20 
 
Purdue pegboard: preferred hand  18 
 
Purdue pegboard: nonpreferred hand  18 
 
Purdue pegboard: both hands  18 
 
Purdue pegboard: assemblies  18 
 
Judgement of line orientation  17 
 
D-KEFS verbal fluency: FAS total  18 
 
D-KEFS verbal fluency: category total  18 
 
D-KEFS verbal fluency: switch accuracy  18 
 
D-KEFS verbal fluency: switch total correct  18 
 
D-KEFS trail making test: visual scanning  18 
 
D-KEFS trail making test: number sequencing  18 
 
D-KEFS trail making test: letter sequencing  16 
 
D-KEFS trail making test: number-letter switch  16 
 
D-KEFS trail making test: motor speed  17 
 
WCST: total errors  20 
 
WCST: perseverative responses  20 
 
WCST: perseverative errors  20 
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WCST: nonperseverative errors  20 
 
WCST: conceptual level responses  20 
Perceived Quality of Life Measures 
   RAND-36: physical functioning  18 
  RAND-36: role limitations due to physical health 18 
 
RAND-36: role limitations due to emotional problems 18 
 
RAND-36: energy/fatigue 17 
 
RAND-36: emotional well-being 17 
 
RAND-36: social functioning 17 
 
RAND-36: pain 17 
 
RAND-36: general health 17 
 
FACT-cog: perceived cognitive impairment  17 
 
FACT-cog: comments from others  17 
 
FACT-cog: perceived cognitive abilities  17 
 
FACT-cog: impact on quality of life 17 
Adaptive Functioning  
 
 
ASR: mean adaptive 18 
 
ASR: personal strengths 18 
 
ASR: internalizing 18 
 
ASR: externalizing  18 
 
ASR: total problems  18 
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Appendix B. Table of descriptive statistics for each neurocognitive measure, by level of 
dysfunction. 
 
Neurocognitive measure (z scores)  Level of dysfunction N Mean 
Std. 
Deviation 
WASI: verbal IQ  Severe 6 -1.44 (1.05) 
Moderate 7 0.19 (0.44) 
Mild 7 0.82 (0.97) 
Total 20 -0.08 (1.25) 
WASI: performance IQ  Severe 6 -0.72 (1.04) 
Moderate 7 0.85 (0.63) 
Mild 7 1.20 (0.73) 
Total 20 0.50 (1.13) 
WASI: full scale IQ  Severe 6 -1.22 (1.02) 
Moderate 7 0.63 (0.50) 
Mild 7 1.12 (0.93) 
Total 20 0.25 (1.28) 
WAIS-3: digit span scaled score Severe 6 7.33 (3.56) 
Moderate 7 10.29 (2.14) 
Mild 7 13.14 (4.10) 
Total 20 10.40 (3.98) 
WAIS-3: digit span  Severe 6 -0.89 (1.19) 
Moderate 7 0.10 (0.71) 
Mild 7 1.05 (1.37) 
Total 20 0.13 (1.33) 
Rey-complex figure_immediate 
recall 
Severe 6 -2.17 (0.98) 
Moderate 7 -0.68 (1.20) 
Mild 7 0.18 (0.37) 
Total 20 -0.83 (1.30) 
Rey-complex figure_delayed 
recall 
Severe 6 -1.92 (1.03) 
Moderate 7 -0.25 (1.42) 
Mild 7 0.13 (0.68) 
Total 20 -0.62 (1.36) 
Rey-complex figure_recognition 
correct 
Severe 6 -0.40 (1.20) 
Moderate 7 -0.30 (1.92) 
Mild 7 0.04 (0.64) 
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Total 20 -0.21 (1.31) 
RAVLT: trial 1  Severe 6 -3.60 (1.72) 
Moderate 7 -1.66 (2.67) 
Mild 6 -0.23 (0.83) 
Total 19 -1.82 (2.30) 
RAVLT: total recall_ trials 1 to 5 
(each trial/15)  
Severe 6 -2.92 (1.46) 
Moderate 7 -0.58 (1.23) 
Mild 6 0.66 (0.98) 
Total 19 -0.93 (1.89) 
RAVLT: trial 8 (delayed recall 
/15)  
Severe 6 -2.14 (1.08) 
Moderate 7 -0.76 (1.96) 
Mild 6 0.74 (1.06) 
Total 19 -0.72 (1.82) 
RAVLT: recognition list A  Severe 6 -3.55 (3.94) 
Moderate 7 -1.87 (2.27) 
Mild 6 0.57 (0.67) 
Total 19 -1.63 (3.00) 
RAVLT: recognition list B  Severe 6 -0.14 (0.99) 
Moderate 7 -0.50 (1.41) 
Mild 6 0.24 (0.83) 
Total 19 -0.15 (1.11) 
SDMT: written  Severe 6 -3.16 (2.14) 
Moderate 6 -0.15 (1.24) 
Mild 7 0.78 (1.51) 
Total 19 -0.75 (2.33) 
SDMT: oral  Severe 6 -2.46 (1.50) 
Moderate 7 -0.50 (1.29) 
Mild 7 0.86 (1.25) 
Total 20 -0.61 (1.87) 
Purdue pegboard: preferred hand  Severe 5 -1.86 (0.74) 
Moderate 7 -0.91 (0.76) 
Mild 6 -0.57 (1.38) 
Total 18 -1.06 (1.08) 
Purdue pegboard: nonpreferred 
hand  
Severe 5 -2.43 (1.99) 
Moderate 7 -1.52 (1.19) 
Mild 6 0.44 (0.88) 
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Total 18 -1.12 (1.76) 
Purdue pegboard: both hands  Severe 5 -2.87 (1.98) 
Moderate 7 -1.63 (1.25) 
Mild 6 0.13 (1.70) 
Total 18 -1.39 (1.95) 
Purdue pegboard: assemblies  Severe 5 -3.65 (2.83) 
Moderate 7 -2.04 (0.70) 
Mild 6 -1.33 (0.51) 
Total 18 -2.25 (1.74) 
Judgement of line orientation  Severe 5 -1.10 (1.30) 
Moderate 6 0.72 (0.53) 
Mild 6 0.85 (0.23) 
Total 17 0.23 (1.15) 
D-KEFS verbal fluency: FAS total  Severe 5 -1.13 (1.30) 
Moderate 6 0.00 (1.10) 
Mild 7 1.05 (1.81) 
Total 18 0.09 (1.65) 
D-KEFS verbal fluency: category 
total  
Severe 5 -1.20 (1.48) 
Moderate 6 1.28 (1.02) 
Mild 7 1.76 (1.56) 
Total 18 0.78 (1.82) 
D-KEFS verbal fluency: switch 
accuracy  
Severe 5 -0.54 (0.77) 
Moderate 6 0.56 (0.83) 
Mild 7 1.05 (0.62) 
Total 18 0.44 (0.96) 
D-KEFS verbal fluency: switch 
total correct  
Severe 5 -1.20 (1.07) 
Moderate 6 0.33 (0.97) 
Mild 7 1.00 (0.77) 
Total 18 0.17 (1.26) 
D-KEFS trail making test: visual 
scanning  
Severe 5 -0.87 (1.43) 
Moderate 7 -0.10 (1.34) 
Mild 6 0.61 (0.53) 
Total 18 -0.07 (1.25) 
D-KEFS trail making test: number 
sequencing  
Severe 5 -1.20 (1.37) 
Moderate 7 0.19 (1.50) 
Mild 6 0.67 (0.52) 
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Total 18 -0.04 (1.38) 
D-KEFS trail making test: letter 
sequencing  
Severe 4 -0.92 (1.40) 
Moderate 6 0.45 (0.69) 
Mild 6 0.39 (0.68) 
Total 16 0.08 (1.03) 
D-KEFS trail making test: 
number-letter switch  
Severe 4 -0.92 (0.57) 
Moderate 6 0.22 (0.50) 
Mild 6 0.67 (0.37) 
Total 16 0.10 (0.78) 
D-KEFS trail making test: motor 
speed  
Severe 5 -0.80 (1.22) 
Moderate 6 0.22 (0.72) 
Mild 6 0.50 (0.28) 
Total 17 0.02 (0.93) 
WCST: total errors  Severe 6 -0.45 (1.33) 
Moderate 7 0.12 (0.98) 
Mild 7 0.39 (0.37) 
Total 20 0.04 (0.97) 
WCST: perseverative responses  Severe 6 -0.10 (1.11) 
Moderate 7 0.09 (0.78) 
Mild 7 0.49 (0.35) 
Total 20 0.17 (0.79) 
WCST: perseverative errors  Severe 6 -0.05 (1.09) 
Moderate 7 0.10 (0.77) 
Mild 7 0.54 (0.30) 
Total 20 0.21 (0.77) 
WCST: nonperseverative errors  Severe 6 -0.74 (1.38) 
Moderate 7 -0.16 (1.09) 
Mild 7 0.21 (0.35) 
Total 20 -0.20 (1.03) 
WCST: conceptual level 
responses  
Severe 6 -0.50 (1.19) 
Moderate 7 0.23 (1.41) 
Mild 7 0.27 (0.30) 
Total 20 0.03 (1.07) 
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Appendix C. Table of demographic data by level of cognitive dysfunction (n = 20).   
 
 
Note. Demographic variables are presented as the count per cell. “Age by development” represents the age at diagnosis dichotomized 
by age 6 to 12 and 12 to 18. “Age by puberty” represents the age at diagnosis dichotomized by pre-puberty (< 10 years of age) and 
puberty onset (>10 years of age). “Medication” represents any medications taken at the time of testing. “Education” represents the 
level of education attained as high school diploma or less (No HSD/HSD) and enrolled or completed post high school education (Post 
HSD).  
 
 
 
Level of cognitive 
dysfunction 
 Demographic variables (count) 
N Sex Age (by 
development)  
Age (by puberty)  Time 
elapsed 
Medication Education 
 
Severe 
 
6 
M = 3 
F = 3 
6-12 = 5 
12-18 = 1 
Pre-puberty = 4 
Puberty onset =  2 
5-15 = 3 
15+ = 3 
No consumption = 1 
Consumption = 5 
No HSD/HSD = 5 
Post HSD = 1 
        
 
Moderate 
 
7 
M = 3 
F = 4 
6-12 = 5 
12-18 = 2 
Pre-puberty = 3 
Puberty onset = 4  
5-15 = 4 
15+ = 3 
No consumption = 2 
Consumption = 5 
No HSD/HSD = 2 
Post HSD = 5 
        
 
Mild 
 
7 
M = 6 
F = 1 
6-12 = 5 
12-18 = 2 
Pre-puberty = 3 
Puberty onset = 4  
5-15 = 4 
15+ = 3 
No consumption = 5 
Consumption = 2 
No HSD/HSD = 6 
Post HSD = 1 
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Appendix D. Table of tumour related data by level of cognitive dysfunction (n = 20).   
 
 
 
Note. Tumour related variables are presented as the count per cell. “Location” represents the tumour location in respect to the 
tenorium. “Pathology” represents the tumour pathology characterized by either an astrocytoma or a different glioma. “Treatment” 
represents the treatment method used as either surgery alone (“Surgery”) or surgery with adjuvant chemo-or radiation therapy 
(“Chemo/Rad”).   “Symptoms” represent the symptoms present at the time of diagnosis as either hydrocephalus and/or seizures 
(“Hydrocephalus/Seizures ”) and no symptoms documented in medical records.   
 
 
Level of cognitive 
dysfunction 
 Tumour variables (count) 
N Sex Location Pathology Treatment Symptoms  
 
Severe 
 
6 
M = 3 
F = 3 
Infratentorial = 3 
Supratentorial = 3 
Astrocytoma = 4 
Other glioma = 2 
Surgery = 5 
Chemo/Rad =  1 
Hydrocephalus/Seizures = 5 
No symptoms = 1 
 
        
 
Moderate 
 
7 
M = 3 
F = 4 
Infratentorial = 3 
Supratentorial = 4 
Astrocytoma = 7 
Other glioma = 0 
Surgery = 4 
Chemo/Rad = 3 
Hydrocephalus/Seizures = 4 
No symptoms = 3 
 
        
 
Mild 
 
7 
M = 6 
F = 1 
Infratentorial = 4 
Supratentorial = 3 
Astrocytoma = 6 
Other glioma = 1 
Surgery = 7 
Chemo/Rad = 0 
Hydrocephalus/Seizures = 3 
No symptoms = 4 
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Appendix E. Table of descriptive statistics for measures of perceived health related quality of life 
(RAND-36), by level of dysfunction. 
 
Subscales (z-scores)                             Level of dysfunction N Mean 
Std. 
Deviation 
Physical functioning  Severe 4 -0.6150 (1.05) 
Moderate 7 0.8371 (0.20) 
Mild 7 0.8886 (0.48) 
Total 18 0.5344 (0.83) 
Role limitations due to physical 
health 
Severe 4 0.2325 (1.06) 
Moderate 7 0.7129 (0.92) 
Mild 7 0.8886 (0.48) 
Total 18 0.6744 (0.80) 
Role limitations due to emotional 
problems 
Severe 4 -0.3900 (1.06) 
Moderate 7 0.1371 (1.00) 
Mild 7 0.8400 (0.00) 
Total 18 0.2933 (0.89) 
Energy/fatigue Severe 4 -0.5425 (0.48) 
Moderate 6 0.2000 (1.22) 
Mild 7 0.5414 (0.80) 
Total 17 0.1659 (0.97) 
Emotional well-being Severe 4 -1.3400 (1.33) 
Moderate 6 0.1350 (0.77) 
Mild 7 0.6186 (0.60) 
Total 17 -0.0129 (1.13) 
Social functioning Severe 4 -1.4975 (0.93) 
Moderate 6 -0.0683 (1.09) 
Mild 7 0.5500 (0.48) 
Total 17 -0.1500 (1.14) 
Pain Severe 4 0.1900 (0.53) 
Moderate 6 0.2983 (1.17) 
Mild 7 0.4757 (0.82) 
Total 17 0.3459 (0.87) 
General health Severe 4 -0.5675 (1.27) 
Moderate 6 0.4583 (1.37) 
Mild 7 1.0571 (1.22) 
Total 17 0.4635 (1.37) 
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Appendix F. Table of descriptive statistics for measures of perceived cognitive quality of life 
(FACT-Cog), by level of dysfunction. 
 
 Subscales (raw scores)               Level of dysfunction N Mean Std. Deviation 
Perceived cognitive 
impairment raw score (/72) 
Severe 4 32.75 (17.73) 
Moderate 6 49.50 (10.01) 
Mild 7 57.57 (10.23) 
Total 17 48.88 (15.09) 
Comments from others raw 
score (/16) 
Severe 4 7.75 (4.27) 
Moderate 6 14.00 (2.45) 
Mild 7 15.43 (0.53) 
Total 17 13.12 (3.90) 
Perceived cognitive abilities 
raw score (/28) 
Severe 4 14.00 (2.94) 
Moderate 6 19.17 (5.38) 
Mild 7 22.14 (3.98) 
Total 17 19.18 (5.21) 
Impact on quality of life raw 
score (/16) 
Severe 4 7.25 (5.74) 
Moderate 6 13.33 (3.44) 
Mild 7 15.00 (1.29) 
Total 17 12.59 (4.51) 
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Appendix G. Table of demographic data for participants who completed the RAND-36 (n = 17), by level of cognitive dysfunction.   
 
 
 
Note. Demographic variables are presented as the count per cell. “Age by development” represents the age at diagnosis dichotomized 
by age 6 to 12 and 12 to 18. “Age by puberty” represents the age at diagnosis dichotomized by pre-puberty (< 10 years of age) and 
puberty onset (>10 years of age). “Medication” represents any medications taken at the time of testing. “Education” represents the 
level of education attained as high school diploma or less (No HSD/HSD) and enrolled or completed post high school education (Post 
HSD).  
 
 
Level of cognitive 
dysfunction 
 Demographic variables (count) 
N Sex Age (by 
development)  
Age (by puberty)  Time 
elapsed 
Medication Education 
 
Severe 
 
4 
M = 1 
F = 3 
6-12 = 3 
12-18 = 1 
Pre-puberty = 2 
Puberty onset =  2 
5-15 = 3 
15+ = 2 
No consumption = 1 
Consumption = 3 
No HSD/HSD = 4 
Post HSD = 0 
        
 
Moderate 
 
6 
M = 3 
F = 3 
6-12 = 5 
12-18 = 1 
Pre-puberty = 3 
Puberty onset = 3 
5-15 = 3 
15+ = 3 
No consumption = 2 
Consumption = 4 
No HSD/HSD = 1 
Post HSD = 5 
        
 
Mild 
 
7 
M = 6 
F = 1 
6-12 = 5 
12-18 = 2 
Pre-puberty = 3 
Puberty onset = 4  
5-15 = 4 
15+ = 3 
No consumption = 5 
Consumption = 2 
No HSD/HSD = 6 
Post HSD = 1 
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Appendix H. Table of demographic data for participants who completed the FACT-Cog (n =17), by level of cognitive dysfunction.   
 
 
 
Note. Demographic variables are presented as the count per cell. “Age by development” represents the age at diagnosis dichotomized 
by age 6 to 12 and 12 to 18. “Age by puberty” represents the age at diagnosis dichotomized by pre-puberty (< 10 years of age) and 
puberty onset (>10 years of age). “Medication” represents any medications taken at the time of testing. “Education” represents the 
level of education attained as high school diploma or less (No HSD/HSD) and enrolled or completed post high school education (Post 
HSD).  
 
 
Level of cognitive 
dysfunction 
 Demographic variables (count) 
N Sex Age (by 
development)  
Age (by puberty)  Time 
elapsed 
Medication Education 
 
Severe 
 
4 
M = 1 
F = 3 
6-12 = 3 
12-18 = 1 
Pre-puberty = 2 
Puberty onset =  2 
5-15 = 3 
15+ = 2 
No consumption = 1 
Consumption = 3 
No HSD/HSD = 4 
Post HSD = 0 
        
 
Moderate 
 
6 
M = 3 
F = 3 
6-12 = 5 
12-18 = 1 
Pre-puberty = 3 
Puberty onset = 3 
5-15 = 3 
15+ = 3 
No consumption = 2 
Consumption = 4 
No HSD/HSD = 1 
Post HSD = 5 
        
 
Mild 
 
7 
M = 6 
F = 1 
6-12 = 5 
12-18 = 2 
Pre-puberty = 3 
Puberty onset = 4  
5-15 = 4 
15+ = 3 
No consumption = 5 
Consumption = 2 
No HSD/HSD = 6 
Post HSD = 1 
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Appendix I. Table of tumour related data for participants who completed the RAND-36, by level of cognitive dysfunction (n = 17).   
 
 
 
Note. Tumour related variables are presented as the count per cell. “Location” represents the tumour location in respect to the 
tenorium. “Pathology” represents the tumour pathology characterized by either an astrocytoma or a different glioma. “Treatment” 
represents the treatment method used as either surgery alone (“Surgery”) or surgery with adjuvant chemo-or radiation therapy 
(“Chemo/Rad”).   “Symptoms” represent the symptoms present at the time of diagnosis as either hydrocephalus and/or seizures 
(“Hydrocephalus/Seizures ”) and no symptoms documented in medical records.   
 
 
 
Level of cognitive 
dysfunction 
 Tumour variables (count) 
N Sex Location Pathology Treatment Symptoms  
 
Severe 
 
4 
M = 1 
F = 3 
Infratentorial = 2 
Supratentorial = 2 
Astrocytoma = 3 
Other glioma = 1 
Surgery = 4 
Chemo/Rad =  0 
Hydrocephalus/Seizures = 4 
No symptoms = 0 
 
        
 
Moderate 
 
6 
M = 3 
F = 3 
Infratentorial = 2 
Supratentorial = 4 
Astrocytoma = 6 
Other glioma = 0 
Surgery = 3 
Chemo/Rad = 3 
Hydrocephalus/Seizures = 4 
No symptoms = 2 
 
        
 
Mild 
 
7 
M = 6 
F = 1 
Infratentorial = 4 
Supratentorial = 3 
Astrocytoma = 6 
Other glioma = 1 
Surgery = 7 
Chemo/Rad = 0 
Hydrocephalus/Seizures = 3 
No symptoms = 4 
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Appendix J. Table of tumour related data for participants who completed the FACT-Cog, by level of cognitive dysfunction (n = 17).   
 
 
Note. Tumour related variables are presented as the count per cell. “Location” represents the tumour location in respect to the 
tenorium. “Pathology” represents the tumour pathology characterized by either an astrocytoma or a different glioma. “Treatment” 
represents the treatment method used as either surgery alone (“Surgery”) or surgery with adjuvant chemo-or radiation therapy 
(“Chemo/Rad”).   “Symptoms” represent the symptoms present at the time of diagnosis as either hydrocephalus and/or seizures 
(“Hydrocephalus/Seizures ”) and no symptoms documented in medical records.   
 
 
 
Level of cognitive 
dysfunction 
 Tumour variables (count) 
N Sex Location Pathology Treatment Symptoms  
 
Severe 
 
4 
M = 1 
F = 3 
Infratentorial = 2 
Supratentorial = 2 
Astrocytoma = 3 
Other glioma = 1 
Surgery = 4 
Chemo/Rad =  0 
Hydrocephalus/Seizures = 4 
No symptoms = 0 
 
        
 
Moderate 
 
6 
M = 3 
F = 3 
Infratentorial = 2 
Supratentorial = 4 
Astrocytoma = 6 
Other glioma = 0 
Surgery = 3 
Chemo/Rad = 3 
Hydrocephalus/Seizures = 4 
No symptoms = 2 
 
        
 
Mild 
 
7 
M = 6 
F = 1 
Infratentorial = 4 
Supratentorial = 3 
Astrocytoma = 6 
Other glioma = 1 
Surgery = 7 
Chemo/Rad = 0 
Hydrocephalus/Seizures = 3 
No symptoms = 4 
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Appendix K. Table of descriptive statistics for measures of adaptive functioning (ASR), by level 
of dysfunction. 
 Subscales (T-scores)                       Level of dysfunction N Mean 
Std. 
Deviation 
Mean adaptive (>  35 is normal) Severe 4 41.25 (11.09) 
Moderate 7 48.29 (13.60) 
Mild 7 53.71 (6.92) 
Total 18 48.83 (11.28) 
Personal strengths (> 35 is 
normal) 
Severe 4 50.25 (5.12) 
Moderate 7 50.29 (12.63) 
Mild 7 48.71 (10.69) 
Total 18 49.67 (10.09) 
Internalizing (< 60 is normal) Severe 4 66.50 (14.48) 
Moderate 7 58.57 (13.05) 
Mild 7 47.71 (13.89) 
Total 18 56.11 (14.90) 
Externalizing (< 60 is normal) Severe 4 64.75 (4.72) 
Moderate 7 54.86 (10.49) 
Mild 7 49.00 (9.97) 
Total 18 54.78 (10.72) 
Total problems (< 60 is normal) Severe 4 66.50 (9.26) 
Moderate 7 56.14 (9.67) 
Mild 7 48.71 (10.26) 
Total 18 55.56 (11.53) 
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Appendix L. Table of demographic data for participants who completed the ASR, by level of cognitive dysfunction (n =18).   
 
 
 
Note. Demographic variables are presented as the count per cell. “Age by development” represents the age at diagnosis dichotomized 
by age 6 to 12 and 12 to 18. “Age by puberty” represents the age at diagnosis dichotomized by pre-puberty (< 10 years of age) and 
puberty onset (>10 years of age). “Medication” represents any medications taken at the time of testing. “Education” represents the 
level of education attained as high school diploma or less (No HSD/HSD) and enrolled or completed post high school education (Post 
HSD).  
 
 
Level of cognitive 
dysfunction 
 Demographic variables (count) 
N Sex Age (by 
development)  
Age (by puberty)  Time 
elapsed 
Medication Education 
 
Severe 
 
4 
M = 1 
F = 3 
6-12 = 3 
12-18 = 1 
Pre-puberty = 2 
Puberty onset =  2 
5-15 = 3 
15+ = 2 
No consumption = 1 
Consumption = 3 
No HSD/HSD = 4 
Post HSD = 0 
        
 
Moderate 
 
7 
M = 3 
F = 4 
6-12 = 5 
12-18 = 2 
Pre-puberty = 3 
Puberty onset = 4  
5-15 = 4 
15+ = 3 
No consumption = 2 
Consumption = 5 
No HSD/HSD = 2 
Post HSD = 5 
        
 
Mild 
 
7 
M = 6 
F = 1 
6-12 = 5 
12-18 = 2 
Pre-puberty = 3 
Puberty onset = 4  
5-15 = 4 
15+ = 3 
No consumption = 5 
Consumption = 2 
No HSD/HSD = 6 
Post HSD = 1 
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Appendix M. Table of tumour related data for participants who completed the ASR, by level of cognitive dysfunction (n = 18).   
 
 
Note. Tumour related variables are presented as the count per cell. “Location” represents the tumour location in respect to the 
tenorium. “Pathology” represents the tumour pathology characterized by either an astrocytoma or a different glioma. “Treatment” 
represents the treatment method used as either surgery alone (“Surgery”) or surgery with adjuvant chemo-or radiation therapy 
(“Chemo/Rad”).   “Symptoms” represent the symptoms present at the time of diagnosis as either hydrocephalus and/or seizures 
(“Hydrocephalus/Seizures”) and no symptoms documented in medical records.   
 
 
 
 
 
Level of cognitive 
dysfunction 
 Tumour variables (count) 
N Sex Location Pathology Treatment Symptoms  
 
Severe 
 
4 
M = 1 
F = 3 
Infratentorial = 2 
Supratentorial = 2 
Astrocytoma = 3 
Other glioma = 1 
Surgery = 4 
Chemo/Rad =  0 
Hydrocephalus/Seizures = 4 
No symptoms = 0 
 
        
 
Moderate 
 
7 
M = 3 
F = 4 
Infratentorial = 3 
Supratentorial = 4 
Astrocytoma = 7 
Other glioma = 0 
Surgery = 4 
Chemo/Rad = 3 
Hydrocephalus/Seizures = 4 
No symptoms = 3 
 
        
 
Mild 
 
7 
M = 6 
F = 1 
Infratentorial = 4 
Supratentorial = 3 
Astrocytoma = 6 
Other glioma = 1 
Surgery = 7 
Chemo/Rad = 0 
Hydrocephalus/Seizures = 3 
No symptoms = 4 
 
        
        
